LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin

Cisplatin is an extensively used chemotherapeutic substance for various types of human malignancies including sarcomas, carcinomas and lymphomas. Yet, the vast application of this drug is hampered by the emergence of chemoresistance in some treated patients. Several mechanisms such as degradation of...

Full description

Saved in:
Bibliographic Details
Published inExperimental and molecular pathology Vol. 123; p. 104602
Main Authors Taheri, Mohammad, Shoorei, Hamed, Tondro Anamag, Farhad, Ghafouri-Fard, Soudeh, Dinger, Marcel E.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.12.2021
Subjects
Apoptosis - drug effects
Cell Proliferation - drug effects
chemoresistance
Cisplatin
Cisplatin - adverse effects
Cisplatin - therapeutic use
Drug Resistance, Neoplasm - genetics
Gene Expression Regulation, Neoplastic - drug effects
Humans
lncRNA
MicroRNAs - genetics
miRNA
Neoplasms - drug therapy
Neoplasms - genetics
Progression-Free Survival
RNA, Long Noncoding - genetics
miRNA
chemoresistance
lncRNA
Cisplatin
Online AccessGet full text

Cover

Abstract Cisplatin is an extensively used chemotherapeutic substance for various types of human malignancies including sarcomas, carcinomas and lymphomas. Yet, the vast application of this drug is hampered by the emergence of chemoresistance in some treated patients. Several mechanisms such as degradation of the membrane transporters by cisplatin have been implicated in the pathogenesis of this event. Recent researches have also indicated the role of long non-coding RNAs (lncRNAs) as well as micoRNAs (miRNAs) in the emergence of resistance to cisplatin in several cancer types. For instance, up-regulation of miR-21 has been associated with resistance to this agent in ovarian cancer, oral squamous cell cancer, gastric malignancy and non-small cell lung cancer (NSCLC). On the other hand, down-regulation of miR-218 has been implicated in emergence of chemoresistance in breast cancer and esophageal squamous cell carcinoma. MALAT1 is implicated in the chemoresistance of bladder cancer cells, NSCLC, gastric cancer and cervical cancer. Most notably, the expression profile of resistance-associated miRNAs and lncRNAs can predict overall survival of cancer patients. Mechanistic assays have revealed that interference with expression of some miRNAs and lncRNAs can reverse the resistance phenotype in cancer cells. In this paper, we review the scientific writings on the role of lncRNAs and miRNAs in the evolution of chemoresistance to cisplatin in cancer cells.
AbstractList Cisplatin is an extensively used chemotherapeutic substance for various types of human malignancies including sarcomas, carcinomas and lymphomas. Yet, the vast application of this drug is hampered by the emergence of chemoresistance in some treated patients. Several mechanisms such as degradation of the membrane transporters by cisplatin have been implicated in the pathogenesis of this event. Recent researches have also indicated the role of long non-coding RNAs (lncRNAs) as well as micoRNAs (miRNAs) in the emergence of resistance to cisplatin in several cancer types. For instance, up-regulation of miR-21 has been associated with resistance to this agent in ovarian cancer, oral squamous cell cancer, gastric malignancy and non-small cell lung cancer (NSCLC). On the other hand, down-regulation of miR-218 has been implicated in emergence of chemoresistance in breast cancer and esophageal squamous cell carcinoma. MALAT1 is implicated in the chemoresistance of bladder cancer cells, NSCLC, gastric cancer and cervical cancer. Most notably, the expression profile of resistance-associated miRNAs and lncRNAs can predict overall survival of cancer patients. Mechanistic assays have revealed that interference with expression of some miRNAs and lncRNAs can reverse the resistance phenotype in cancer cells. In this paper, we review the scientific writings on the role of lncRNAs and miRNAs in the evolution of chemoresistance to cisplatin in cancer cells.
Cisplatin is an extensively used chemotherapeutic substance for various types of human malignancies including sarcomas, carcinomas and lymphomas. Yet, the vast application of this drug is hampered by the emergence of chemoresistance in some treated patients. Several mechanisms such as degradation of the membrane transporters by cisplatin have been implicated in the pathogenesis of this event. Recent researches have also indicated the role of long non-coding RNAs (lncRNAs) as well as micoRNAs (miRNAs) in the emergence of resistance to cisplatin in several cancer types. For instance, up-regulation of miR-21 has been associated with resistance to this agent in ovarian cancer, oral squamous cell cancer, gastric malignancy and non-small cell lung cancer (NSCLC). On the other hand, down-regulation of miR-218 has been implicated in emergence of chemoresistance in breast cancer and esophageal squamous cell carcinoma. MALAT1 is implicated in the chemoresistance of bladder cancer cells, NSCLC, gastric cancer and cervical cancer. Most notably, the expression profile of resistance-associated miRNAs and lncRNAs can predict overall survival of cancer patients. Mechanistic assays have revealed that interference with expression of some miRNAs and lncRNAs can reverse the resistance phenotype in cancer cells. In this paper, we review the scientific writings on the role of lncRNAs and miRNAs in the evolution of chemoresistance to cisplatin in cancer cells.Cisplatin is an extensively used chemotherapeutic substance for various types of human malignancies including sarcomas, carcinomas and lymphomas. Yet, the vast application of this drug is hampered by the emergence of chemoresistance in some treated patients. Several mechanisms such as degradation of the membrane transporters by cisplatin have been implicated in the pathogenesis of this event. Recent researches have also indicated the role of long non-coding RNAs (lncRNAs) as well as micoRNAs (miRNAs) in the emergence of resistance to cisplatin in several cancer types. For instance, up-regulation of miR-21 has been associated with resistance to this agent in ovarian cancer, oral squamous cell cancer, gastric malignancy and non-small cell lung cancer (NSCLC). On the other hand, down-regulation of miR-218 has been implicated in emergence of chemoresistance in breast cancer and esophageal squamous cell carcinoma. MALAT1 is implicated in the chemoresistance of bladder cancer cells, NSCLC, gastric cancer and cervical cancer. Most notably, the expression profile of resistance-associated miRNAs and lncRNAs can predict overall survival of cancer patients. Mechanistic assays have revealed that interference with expression of some miRNAs and lncRNAs can reverse the resistance phenotype in cancer cells. In this paper, we review the scientific writings on the role of lncRNAs and miRNAs in the evolution of chemoresistance to cisplatin in cancer cells.
ArticleNumber 104602
Author Taheri, Mohammad
Dinger, Marcel E.
Shoorei, Hamed
Ghafouri-Fard, Soudeh
Tondro Anamag, Farhad
Author_xml – sequence: 1
  givenname: Mohammad
  surname: Taheri
  fullname: Taheri, Mohammad
  organization: Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
– sequence: 2
  givenname: Hamed
  surname: Shoorei
  fullname: Shoorei, Hamed
  organization: Department of Anatomical Sciences, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
– sequence: 3
  givenname: Farhad
  surname: Tondro Anamag
  fullname: Tondro Anamag, Farhad
  organization: Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
– sequence: 4
  givenname: Soudeh
  surname: Ghafouri-Fard
  fullname: Ghafouri-Fard, Soudeh
  email: s.ghafourifard@sbmu.ac.ir
  organization: Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
– sequence: 5
  givenname: Marcel E.
  surname: Dinger
  fullname: Dinger, Marcel E.
  email: m.dinger@unsw.edu.au
  organization: School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33422487$$D View this record in MEDLINE/PubMed
BookMark eNp9kMtq3DAUQEVJaSaPLygULbvx9MqSH1p0EULaBIYWSrvqQsjyFdzBll1JEzJ_H89MsukiKz045yKdC3YWpoCMfRSwFiDqL9v1Hp_GeV1CKZYbVUP5jq0E6LoAraoztgIQqlAtwDm7SGkLABpE-YGdS6nKUrXNiv3dBPfrx03iNvR8pON2tjGTo9lm5BR4jxnjSMFmmgKfPE8YEmV6pLw_HJ0NDiN3OAyJ54k7SvOwwOGKvfd2SHj9sl6yP9_uft_eF5uf3x9ubzaFk5XOhUKoKqGcslZJ12rthfe9RRQlIHovGy913dZN1SlhwUmlG9d1DbgOHFaVvGSfT3PnOP3bYcpmpHR4jg047ZIpVVO3SlW6XtBPL-iuG7E3c6TRxr15DbIA-gS4OKUU0RtH-fjzHC0NRoA5xDdbc4xvDvHNKf7iyv_c1_FvW19PFi6JHgmjSY5wSdpTRJdNP9Gb_jPDqp9O
CitedBy_id crossref_primary_10_1007_s13577_022_00748_8
crossref_primary_10_1080_08827508_2024_2428689
crossref_primary_10_1002_tox_23940
crossref_primary_10_1016_j_gendis_2023_06_032
crossref_primary_10_1038_d41586_024_02719_5
crossref_primary_10_3389_fgene_2021_767590
crossref_primary_10_1111_cbdd_14424
crossref_primary_10_1007_s11010_023_04908_8
crossref_primary_10_1111_cas_15703
crossref_primary_10_1007_s00018_022_04552_3
crossref_primary_10_1007_s11033_024_09552_z
crossref_primary_10_3389_fmolb_2022_864839
crossref_primary_10_3390_ijms24108939
crossref_primary_10_1007_s10528_024_10795_5
crossref_primary_10_1186_s11658_024_00676_5
crossref_primary_10_1155_2021_3088723
crossref_primary_10_1080_21655979_2021_1939577
crossref_primary_10_1177_15330338211033044
crossref_primary_10_3233_CBM_220145
crossref_primary_10_3390_ijms24021244
crossref_primary_10_1186_s13048_024_01429_w
crossref_primary_10_1371_journal_pone_0267017
crossref_primary_10_3389_fcell_2021_795874
crossref_primary_10_1080_21655979_2021_2005927
crossref_primary_10_2478_raon_2023_0033
crossref_primary_10_1007_s10528_022_10220_9
crossref_primary_10_3390_nu15153407
crossref_primary_10_2174_0113894501294182240401060343
crossref_primary_10_18632_aging_205819
crossref_primary_10_1097_CAD_0000000000001289
crossref_primary_10_1007_s00109_024_02488_8
crossref_primary_10_1080_1120009X_2023_2213490
crossref_primary_10_3389_fcell_2021_707424
crossref_primary_10_3390_cancers16091729
crossref_primary_10_1002_ptr_7305
Cites_doi 10.3390/cancers12040856
10.1016/j.gene.2015.11.013
10.1038/cdd.2014.221
10.1038/s41388-018-0459-x
10.1016/j.abb.2017.05.001
10.3892/or.2014.3657
10.1177/1010428317715155
10.1038/onc.2015.84
10.1007/s13277-015-4081-z
10.1186/s13046-017-0528-y
10.1016/j.eurox.2019.100103
10.2147/CMAR.S240695
10.2147/OTT.S146423
10.3892/or.2015.3996
10.3389/fendo.2018.00402
10.1016/j.canlet.2019.10.044
10.1371/journal.pone.0117809
10.1111/cas.13104
10.4149/neo_2015_051
10.18632/oncotarget.23483
10.1016/j.omtn.2019.05.007
10.18632/oncotarget.25326
10.2147/OTT.S239425
10.1016/j.biopha.2018.10.080
10.1016/j.canlet.2016.08.024
10.1186/s12935-019-0943-6
10.5483/BMBRep.2018.51.9.104
10.2147/OTT.S197454
10.2147/OTT.S212649
10.1016/j.neuint.2018.03.011
10.1186/s13578-018-0260-0
10.1016/j.omtn.2019.02.017
10.1186/s12885-018-4233-9
10.1093/abbs/gmx078
10.1016/j.bbrc.2016.11.037
10.1016/j.biopha.2018.07.059
10.1042/BSR20194342
10.3233/CBM-170452
10.1080/21655979.2019.1710925
10.3892/mmr.2017.6897
10.18632/oncotarget.8229
10.3892/or.2017.5532
10.1002/jcp.28823
10.1186/s12935-016-0305-6
10.1080/15384101.2017.1361071
10.1038/s41419-018-0390-7
10.18632/oncotarget.22138
10.1007/s12031-018-1177-0
10.1016/j.biopha.2018.02.130
10.3390/ijms20143540
10.21037/jtd.2016.11.75
10.1159/000495169
10.1016/j.gene.2015.07.002
10.1111/cei.13406
10.18632/oncotarget.4762
10.1080/15384047.2017.1385679
10.1080/15384101.2019.1704537
10.1016/j.apsb.2019.11.001
10.1177/1533034615618849
10.18632/oncotarget.16610
10.1007/s13277-015-3921-1
10.3892/mmr.2015.3897
10.18632/oncotarget.23249
10.1089/hum.2017.256
10.1002/jcp.29442
10.1371/journal.pone.0150026
10.1042/BSR20180547
10.1007/s13277-016-5448-5
10.1007/s13277-015-4500-1
10.1016/j.ebiom.2018.08.001
10.1007/s13277-015-4267-4
10.1016/j.biopha.2019.108869
10.1159/000495835
10.1016/j.prp.2019.01.042
10.1016/j.biopha.2016.11.139
10.1007/s00280-017-3435-1
10.1016/j.biopha.2019.108633
10.7150/ijbs.32460
10.1111/jcmm.12760
10.2147/OTT.S210732
10.1038/onc.2016.201
10.1159/000460618
10.2147/OTT.S225010
10.18632/oncotarget.10736
10.1007/s12079-018-0479-x
10.1016/j.ccr.2010.04.011
10.3892/mmr.2016.5413
10.1016/j.biopha.2018.07.076
10.18632/oncotarget.6852
10.1186/s12964-018-0270-x
10.1371/journal.pone.0223035
10.2147/CMAR.S231375
10.1002/jcb.29402
10.1186/s12885-015-1713-z
10.18632/oncotarget.27531
10.1002/biof.1616
10.1186/s12935-020-1164-8
10.1016/j.biopha.2017.06.089
10.1124/mol.62.5.1154
10.1097/CAD.0000000000000888
10.1038/onc.2015.271
10.1016/j.biopha.2019.108662
10.1093/abbs/gmz112
10.1002/jcb.28244
10.2147/OTT.S214104
10.1038/srep43109
10.1371/journal.pone.0121547
10.1186/s12943-020-01168-8
10.1007/s00280-019-03808-3
10.1002/jbt.22452
10.18632/aging.102575
10.2147/IJN.S221383
10.1080/1061186X.2019.1644651
10.1007/s13277-014-2814-z
10.7150/ijbs.16529
10.1002/cam4.1253
10.4314/tjpr.v18i1.4
10.3892/mmr.2017.7081
10.1016/j.bbrc.2019.08.040
10.1002/mc.22656
10.1007/s10616-017-0134-z
10.7150/jca.25814
10.3389/fgene.2019.00280
10.1007/s00432-018-2761-y
10.1186/s13046-015-0145-6
10.1038/srep17618
10.18632/aging.101876
10.1159/000490834
10.1097/CAD.0000000000000227
10.2147/OTT.S232769
10.1038/s41419-018-0793-5
10.1002/cbin.11071
10.18632/oncotarget.3659
10.1080/15384047.2018.1450119
10.1002/jcb.29370
10.1007/s00018-017-2485-1
10.18632/oncotarget.13424
10.18632/oncotarget.13708
10.2147/CMAR.S243796
10.18632/aging.101907
10.1016/j.biopha.2019.109740
10.7555/JBR.33.20180078
10.3892/or.2014.3664
10.1124/pr.111.005637
10.1038/cgt.2017.6
10.1016/j.ejphar.2014.07.025
10.1007/s13277-014-2898-5
10.1042/BSR20170080
10.1042/BSR20182101
10.1002/jcp.29040
10.1002/cam4.1682
10.18632/oncotarget.9712
10.1016/j.biopha.2017.01.058
10.1016/j.ijbiomac.2017.10.154
10.1038/s41389-019-0170-y
10.1159/000491476
10.1016/j.bbrc.2018.02.091
10.1038/srep26093
10.1038/s41389-018-0050-x
10.1186/s12967-015-0488-y
10.2147/OTT.S228199
10.1016/j.lfs.2019.117162
10.1002/jcb.27327
10.1093/carcin/bgy189
10.2147/IJN.S131516
10.1016/j.canlet.2019.10.004
10.1124/mol.106.022624
10.1038/cgt.2014.73
10.1002/1873-3468.12566
10.3892/ol.2015.4000
10.3389/fgene.2018.00555
10.1016/S0140-6736(20)30211-7
10.18632/oncotarget.15781
10.3892/or.2014.3640
10.1002/jcb.26865
10.1096/fj.201701456RR
10.1007/s10529-017-2392-4
10.1016/j.canlet.2015.03.045
10.1186/s13059-018-1604-0
10.3892/ijo.2016.3392
10.3892/ijo.2015.3143
10.1042/BSR20180375
10.1016/j.bcp.2019.01.009
10.1073/pnas.162491399
10.1371/journal.pone.0114586
ContentType Journal Article
Copyright 2021 Elsevier Inc.
Copyright © 2021 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2021 Elsevier Inc.
– notice: Copyright © 2021 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.yexmp.2021.104602
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1096-0945
ExternalDocumentID 33422487
10_1016_j_yexmp_2021_104602
S0014480021000010
Genre Journal Article
Review
GroupedDBID ---
--K
--M
-~X
.55
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29G
3O-
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAXUO
ABBQC
ABFRF
ABGSF
ABJNI
ABLVK
ABMAC
ABMZM
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
COF
CS3
DM4
DOVZS
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
GROUPED_DOAJ
HDY
HLW
HMK
HMO
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
LCYCR
LG5
LX2
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SBG
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSU
SSZ
T5K
UHS
UNMZH
WUQ
X7M
XPP
ZGI
ZMT
ZU3
~G-
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACIEU
ACRPL
ACVFH
ADCNI
ADNMO
ADVLN
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c359t-4e05514c4aa43c899f1ffdaee120eeff37f3968675b41a0c3497cbb70cb0ce553
IEDL.DBID .~1
ISSN 0014-4800
1096-0945
IngestDate Fri Jul 11 06:24:44 EDT 2025
Thu Apr 03 07:05:44 EDT 2025
Tue Jul 01 01:56:50 EDT 2025
Thu Apr 24 22:59:55 EDT 2025
Fri Feb 23 02:42:57 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords miRNA
chemoresistance
lncRNA
Cisplatin
Language English
License Copyright © 2021 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c359t-4e05514c4aa43c899f1ffdaee120eeff37f3968675b41a0c3497cbb70cb0ce553
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 33422487
PQID 2476844596
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2476844596
pubmed_primary_33422487
crossref_citationtrail_10_1016_j_yexmp_2021_104602
crossref_primary_10_1016_j_yexmp_2021_104602
elsevier_sciencedirect_doi_10_1016_j_yexmp_2021_104602
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2021
2021-12-00
20211201
PublicationDateYYYYMMDD 2021-12-01
PublicationDate_xml – month: 12
  year: 2021
  text: December 2021
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Experimental and molecular pathology
PublicationTitleAlternate Exp Mol Pathol
PublicationYear 2021
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Sun, Tang, Li, Guo, Cheng, Song (bb0120) 2018; 8
Jin, Liu, Wang (bb0300) 2018 Aug 31; 38
Zhao, Nie, Wang, Lin (bb1025) 2016; 576
Li, Zhang, Liu, Zhang, Zhong, Wang (bb2040) 2018; 18
Zhang, Ma, Zhang, Xie, Wang, Li (bb0990) 2018; 9
Chen, Liu, Meng, Sun, Jin, Jia (bb0065) 2019; 120
Zheng, Xu, Suo, Xu, Ni, Gu (bb1045) 2016; 6
Ge, Cao, Yao, Jing, Wang, Li (bb0190) 2019; 12
Sui, Meng, Li, Jiang (bb0650) 2015; 13
Fan, Xu, Tu (bb0135) 2020; 121
Song, Li (bb0635) 2017; 108
Tang, Yuan, Li, Wang, Xie, Zhu (bb0670) 2018; 497
Abolghasemi, Tehrani, Yousefi, Karimian, Mahmoodpoor, Ghamari (bb0005) 2020 Jun; 235
Lin, Okuda, Holzer, Howell (bb0395) 2002; 62
Sun, Zhu, Zhang, Zhang, Song, Rahman (bb0660) 2017; 39
Yu, Zhou, Yao, Meng, Lang (bb9247) 2019; 16
Wang, Yu, Liu, Wang, Xu, Cui (bb9243) 2016; 15
Liu, Xu, Li, Li, Hu (bb0465) 2018; 22
Xie, Huang, Zhang, Wei, Gao, Li (bb0840) 2019; 10
Zhu, Tang, Wang, Duan, Zhou, Zhou (bb1110) 2016; 11
Fan, Chen, Lv, Tang, Sun, Liu (bb0140) 2015; 362
Chikuda, Otsuka, Shimomura, Ito, Miyazaki, Takahashi (bb0100) 2020; 12
Tang, Yu, Zeng, Chen (bb0680) 2020; 12
Tang, Cheng, She, Jiang, Chen, Yang (bb0675) 2018; 107
Wu, Hu, Yan, Qi, Zhang, Zhu (bb2010) 2020; 235
Ma, Zhou, Li, Hu, Zhang, Liu (bb0505) 2018; 118
Xie, Ji, Lin, Jin, Zhang, Huang (bb0825) 2020
Qin, Yu, Zhou, Shi, Hu, Xu (bb0560) 2017; 12
Lei, Li, Tong, Qi, Hu, Cui (bb0325) 2015; 10
Ma, Cao, Ding (bb0495) 2020; 46
Peng, Croce (bb0535) 2016; 1
Xu, Lai, Weng, Tan, Li, Chen (bb0865) 2019; 11
Fang, Chen, Zhi (bb0155) 2016; 22
Wang, Chunyan, Zhou, He, Ma, Ga (bb0715) 2017; 21
Cui, Wu, Tian, Wang, Lu, Huang (bb0105) 2018; 39
Fan, Zhou, Zheng, Deng, Yi, Huang (bb9239) 2017; 88
Su, Li, Cao, Xiao, Shi (bb0645) 2017; 10
Xu, Fu, Tao, OuYang, Kong, Jiang (bb0860) 2015; 6
Jiang, Ni, Cui, Wang, Zhuo (bb0285) 2019; 9
Li, Xu, Wang, Wang, Wu (bb0350) 2018; 21
Wang, Wang, Zhang, Lu, Chu, Yang (bb0700) 2018; 9
Fang, Zhao, Xie, Sun, Wang, Qiao (bb0170) 2017; 6
Bao, Zhang, Lu, Guo, Dong, Chen (bb0025) 2020; 16
Chen, Zhang, Kuai, Cheng, Fang, Li (bb2025) 2017; 39
Holzer, Manorek, Howell (bb0235) 2006; 70
Li, Niu, Qin, Yang, Wang, Yu (bb9255) 2019; 17
Zhang, Yao, Guo, Huang, Huai, Ye (bb0995) 2018; 9
Wang, Zhang, Zhang, Chu (bb9242) 2016; 20
Bissey, Law, Bruce, Shi, Renoult, Chua (bb0030) 2018; 7
Li, Xing, Wu, Xue (bb9240) 2018; 22
Wu, W-p, Lei, K-q, Lin, Shi (bb0795) 2019; 13
Song, Lu, Sun, Yang, Wang, Wang (bb0630) 2017; 482
Liu, Pan, Ma, Wang, Yao, Wei (bb0400) 2017; 16
Shi, Xi, Xu, Peng, Zhang (bb0615) 2019; 109
Dou, Ge, Wang, Xu, Zhang, Seng (bb0125) 2019; 12
Miao, Gao, Chen, Chen, Meng, Lou (bb0515) 2019; 39
Zhang, Yang, Shao, Wei (bb0985) 2016; 20
Zhu, Shen, Yin, Long, Chen, Feng (bb1095) 2017 Jun 13; 8
Lin, Xie, Lu, Hu, Chang (bb0375) 2018; 41
Zhang, Hu, Wang, Zhang, Wei, Li (bb0965) 2017; 80
Li, Yin, He, Huang, Zhu, Gao (bb9251) 2017; 8
Samuel, Pink, Caley, Currie, Brooks, Carter (bb0580) 2016; 37
Luo, Wu, Zhou, Yuan, Li, Chen (bb0490) 2020; 15
Cao, Chen, Ou, Liu, Zou (bb0040) 2017; 93
Ma, Yuwen, Chen, Zheng, Gao, Fan (bb2015) 2019; 14
Cheng, Zhao, Liu (bb0085) 2019; 23
Tian, Xu, Li, Hao (bb0690) 2017; 9
Li, Ma, Yang, Suo, Dai, Liu (bb0335) 2020 Feb; 121
Zhu, Shan, Liu, Zhou, Zhang, Wang (bb1090) 2019; 33
Guo, Jin, Wu, Yang, Du, Gong (bb0215) 2018; 35
Lin, Chen, Hsieh, Yang, Lai, Chuang (bb0390) 2019; 40
You, Li, Zhang, Zhang, Cao (bb0930) 2020; 12
Liu, Liu, Zhou, Mi, Wang (bb0405) 2015; 8
Xu, Tang, Wang (bb0855) 2018; 22
Huang, Ren, Ding, Yang, Wen, Peng (bb0265) 2020; 43
Liu, Li, Gao, Cui, Ma, Zhou (bb0450) 2016; 8
Wang, Chen, Ma, Li (bb0735) 2017; 10
Chen, Li, Li, Cao (bb9248) 2020
Amini-Farsani, Sangtarash, Shamsara, Teimori (bb0015) 2018; 70
Chen, Jiao, Wang, Hu, Tang, Chen (bb0570) 2016; 7
Kirave, Gondaliya, Kulkarni, Rawal, Garg, Jain (bb0320) 2020; 11
Liu, Tang, Li, Yang (bb9241) 2016; 7
Wu, Liu, Zhang (bb0270) 2020; 19
Yan, Su, Zhang, Gao (bb9256) 2019; 55
Li, Wang, Qiao, Zhang, Wang, Cong (bb0370) 2020; 521
Jiang, Wu, Wang, Huang, Feng (bb0290) 2016; 7
Shen, Lei, Du (bb0605) 2020; 19
Yin, Nie, Zhang, Xie, He (bb0925) 2015; 34
Li, Zhang, Shang, Xu (bb0340) 2019; 23
Zhuang, Shi, Zhang, Ding, Shan, Shan (bb1115) 2015; 36
Shen, Pouliot, Hall, Gottesman (bb0600) 2012; 64
Liu, Li, Cui, Chen, Li, Li (bb0455) 2019; 51
Xia, He, Liu, Wang, Chen (bb0815) 2015; 12
Zhou, Jin, Jia, Yan, Zhang (bb1075) 2015; 34
An, Yang (bb0020) 2020; 242
Yu, Gao (bb0935) 2020; 24
Chen, Zhu, Lu, Liu (bb0050) 2020; 11
Yu Z., Cao W., Ren Y., Zhang Q., Liu J., ATPase copper transporter A, negatively regulated by miR-148a-3p, contributes to cisplatin resistance in breast cancer cells. Clin. Transl. Med.
Yang, Fang, Di, Ying, Tan, Gu (bb0900) 2015; 10
Xu, Guo, Liu, Chen, Yan, Liu (bb0845) 2018; 8
Zhu, Shen, Yin, Long, Xie, Liu (bb1105) 2016; 35
Zhang, He, Zhang, Chen (bb2020) 2018; 47
Yang, Xiao, Cai, Jin, Li (bb0895) 2020; 13
Xiao, Li, Pan, Ye, He, Tian (bb0820) 2019; 120
Wang, Zhou, Xie, Hu, Chen, Hu (bb0695) 2015; 62
Du, Zhu, Zhou, Huang, Zhu, Xu (bb0130) 2016; 37
Yi, Tu, Liu, Zhang, Batra, Yu (bb2045) 2020; 10
Shao, Chen, Soutto, Zhu, Lu, Romero-Gallo (bb0595) 2019; 33
Zhang, Deng, Liu, Ning, Yang, Liu (bb0960) 2020; 19
Zhen, Fang, Zhao, Luo, Liu, Fu (bb2005) 2017; 36
Chen, Zhou, Dong, Qu, Gong, Han (bb0055) 2020; 395
Wu, Pu, Wang, Cao, Xu, Xu (bb0790) 2016; 11
Song, Zhou, Gan, Li, Xu, Zhang (bb0640) 2019; 120
Wang, Zhang, Yu, Li, Wang, Chang (bb0720) 2020 Jan 1; 468
Zhu, Shen, Yin, Long, Chen, Feng (bb1100) 2017; 8
Liu, Yang, Zhao, Chi, Wang, Sun (bb0480) 2019; 11
Wang, Hou, Zhan, Shen, Xue (bb0730) 2018; 22
Ishida, Lee, Thiele, Herskowitz (bb0275) 2002; 99
Harel, Ben-Moshe, Aylon, Bublik, Moskovits, Toperoff (bb0225) 2015; 22
Hu, Zhang, Wang, Zhang, Wei, Li (bb0250) 2017; 18
Wang, Zhang, Jiang, Zhang, Zhang, Silayiding (bb0710) 2020; 5
Hao, Hao, Ding, Wen, Xf, Wang (bb0210) 2017; 591
Liu, Xing, Rong (bb0435) 2018; 39
Yu, Li, Li, Lü, Zhao, Li (bb2000) 2019; 10
Yang, Zhan, Chen, Chen, Zhang, Xu (bb5500) 2017; 7
Liu, Wan, Lu, Sun, Pan, Zhang (bb0430) 2015; 10
Qiao, Qiao, Jin, Liu, Zheng, Wang (bb0550) 2020; 24
Shi, Xiao, Mao, He, Ding, Huang (bb0620) 2018; 9
Xi, Si, Nan (bb9252) 2019; 54
Liu, Zhang, Luo, Zeng, Xu, Zhang (bb0420) 2019; 28
Zheng, Chen, Yuan, Luo, Liu, Xie (bb1035) 2017; 36
Feng, Zou, Hu, Li, Zhou, He (bb0175) 2017; 623
Tian, Hou, Xiong, Huang, She, Bi (bb0685) 2015; 33
Zhou, Cheng, He, Meng, Ye, Chen (bb1055) 2017; 14
Chen, Zhang, Shi, Lian, Tu, Han (bb0075) 2015; 47
Han, Zhen, Ye, Lu, Wang, Li (bb0220) 2017; 41
Zhang, Xu, Gao, Wang, Ding, Zhang (bb0970) 2020; 10
Liu, Chen, Sun, Lei, Li, Zhou (bb0460) 2017; 49
Seidl, Panzitt, Bertsch, Brcic, Schein, Mack (bb0585) 2020; 469
Li, Wang, Ding, Zheng, Ma, Wang (bb0355) 2016; 16
Zuo, Luo, Huang, Lou, Li (bb1120) 2019; 18
Liu, Bissey, Teng, Law, Shi, Bruce (bb0410) 2019
Yuwen, Sheng, Liu, Wenyu, Shu (bb0945) 2017; 21
Zhang, Xu, Ni, Li, Zhou, Xu (bb1005) 2016; 12
Sun, Cai, Yung, Zhou, Li, Zhang (bb9245) 2019; 38
Xu, Guo, Liu, Chen, Yan, Liu (bb0850) 2018; 8
Dai, Zhang, Li (bb0110) 2020; 12
Lin, Zhang, An, Li, Fang, Pan (bb0385) 2019; 8
Sheng, Zhang, Wang, Ding, Song, Zhao (bb0610) 2019; 200
Li, Yang, Wang, Yi, Jia, Chen (bb0345) 2015; 10
Yu, Li, Jiang, Zhang, Yao (bb9244) 2018; 22
Wu, Zhou, Pan, Sun, Xu, Shi (bb0780) 2018; 47
Phatak, Byrnes, Mansour, Liu, Cao, Li (bb0540) 2016; 35
Sun, Ping, Tian, Zou, Liu, Zu (bb0665) 2018; 51
Kim, Jang, Sung, Song, Kim, Lee (bb0315) 2019; 20
Wang, Cheng, Li, Pan, Li, Ren (bb9258) 2017; 8
Zhang, Huang, Guo, Li (bb9237) 2018; 106
Meng, Zhao, Bai, Zhao, Wang, Xue (bb0510) 2020; 43
Cao, Wan, Li, Tang (bb0045) 2018; 51
Cai, Dong, Wang (bb0035) 2018; 22
Li, Zhu (bb8259) 2019; 215
Liu, Niu, Lin, Tian (bb0475) 2017; 24
Zhao, Liu, Wang, Wu, Ding, Guo (bb1010) 2015; 33
Liu, Tai, Ma (bb0415) 2018; 19
Huang, Lou, Pan, Ye, Yin, Li (bb0260) 2019; 11
Zhao, Yu, Ding, Zhao, Wang, Wu (bb1015) 2016; 7
O'Brien, Hayder, Zayed, Peng (bb0520) 2018; 9
Zhang, Li, Chao, He, Liu, Yuan (bb2035) 2018; 16
Wang, Wang, Xu, Meng, Huang, Jiang (bb0770) 2020
Zhao, Fu, Liao, Dai, Jiang, Pan (bb1020) 2015; 15
Cheng, Qin, Zhi, Wang, Qin (bb0080) 2018; 107
Ghasabi, Majidi, Mansoori, Mohammadi, Shomali, Shirafkan (bb0205) 2019; 234
Jiang, Jiang, Jia, Qiao, Zhang (bb0295) 2018; 51
Shindo, Niinuma, Nishiyama, Shinkai, Kitajima, Kai (bb0625) 2018; 9
Peng, Zhang, Du, Tan (bb0530) 2015; 33
Gao, Wang (bb0180) 2019; 23
Wang, Chen, Meng, Jing, Lu, Yang (bb0745) 2015; 5
Hu, Yang, Wang, Wang, Sun, Xu (bb0255) 2018; 38
Chen, Han, Hu, Chen (bb9249) 2019; 83
Fang, Chen, Yuan, Liu, Jiang (bb0160) 2018; 101
Yang, Li, Luo (bb0890) 2020; 13
Zhang, Huang, Wang, Chang, Zheng (bb1000) 2017; 74
Yang, Wu, Wang, Jin, Miao, Wu (bb0880) 2020; 111817
Fang, Chen, Wu, Yin, Li, Huang (bb0150) 2017; 7
Wu, Zhang, Qin, Geng, Zuo, Zhao (bb0805) 2020; 105195
Yuan, Zhao, Chen, Wang, Bie, Wu (bb0940) 2020; 19
Hang, Sun, Jiang, Li (bb9253) 2015; 26
Li, Shi, Dong, Zhu, Liu, Liu (bb0365) 2019; 10
Liu, Tian, Zhang, Zhao, Ma (bb0445) 2018
Zhang, Guo, Zhang, Fan, Qin, Dong (bb0975) 2017; 56
Zeng, Hu, Li, Xia (bb0955) 2016; 20
Zhu, Zhou, Du, Huang, Zhu, Xu (bb1085) 2016; 14
Ye, Yin, Su, Bai, Zhang, Hei (bb0915) 2016; 7
Yan, Dang, Liu, Zhang, Zhang (bb0870) 2016; 37
Zang, Zhao, Gao, Li, Zhong, Gao (bb0950) 2019; 12
Wang, Li, Wu, Ge, Zhang, Gong (bb0705) 2016; 71
Ye, Hao, Cai, Wang, Huang (bb0910) 2016; 37
An, Huang, Han, Wang (bb0330) 2020; 31
Chi, Mao, Shen, Chen, Chen, Hou (bb0095) 2018; 29
Xie, Wang, Zhao, Zhang, Qin, Yang (bb0835) 2017; 8
Wang, Li, Shi (bb0755) 2019; 2019
Liu, Qie, Yang, Song (bb0425) 2018; 14
Wu, Xie, Shi, Wang (bb0800) 2020; 40
Xie, Liu, Li, Yang, Pan, Wei (bb0830) 2019; 20
Zhu, Yang, Yang (bb1080) 2020; 19
Zhao, Zhang, Yao, Tao (bb1030) 2015; 22
Wang, Zhang, Zheng, Zhong, Tian, Yin (bb0765) 2016; 382
Jin, Liu, Wang (bb0305) 2018; 38
Ishida, McCormick, Smith-McCune, Hanahan (bb0280) 2010; 17
Ou, Zhai, Wu, Li (bb0525) 2015; 572
Lu, Shan, Li, Yang (bb0485) 2017; 86
Wu, Chen, Ye, Wang, Zhang, Sheng (bb0785) 2019; 115
Wang, Wu, Fang, Huang, Zhu (bb0725) 2019; 12
Ma, Xie, Ma, Pang, Xiong, Zheng (bb0500) 2017; 21
Wang, Guo, Yao, Helms (bb0750) 2017; 37
Zhou, Ma, Zhou, Jiang, Rao, Zhao (bb1060) 2016; 48
Ma, Gao, Lou, Zhang, Yuan, Wu (bb9259) 2017; 16
Zhou, Hu
Zhou (10.1016/j.yexmp.2021.104602_bb1070) 2016; 37
Ou (10.1016/j.yexmp.2021.104602_bb0525) 2015; 572
Fang (10.1016/j.yexmp.2021.104602_bb0160) 2018; 101
Sun (10.1016/j.yexmp.2021.104602_bb0660) 2017; 39
Ishida (10.1016/j.yexmp.2021.104602_bb0280) 2010; 17
Liu (10.1016/j.yexmp.2021.104602_bb0475) 2017; 24
Wang (10.1016/j.yexmp.2021.104602_bb0760) 2018; 9
Wang (10.1016/j.yexmp.2021.104602_bb0755) 2019; 2019
Li (10.1016/j.yexmp.2021.104602_bb2030) 2018; 22
Li (10.1016/j.yexmp.2021.104602_bb0355) 2016; 16
Li (10.1016/j.yexmp.2021.104602_bb0365) 2019; 10
Liu (10.1016/j.yexmp.2021.104602_bb0455) 2019; 51
Seidl (10.1016/j.yexmp.2021.104602_bb0585) 2020; 469
Chen (10.1016/j.yexmp.2021.104602_bb0050) 2020; 11
Zhang (10.1016/j.yexmp.2021.104602_bb0990) 2018; 9
Zhao (10.1016/j.yexmp.2021.104602_bb1030) 2015; 22
Xi (10.1016/j.yexmp.2021.104602_bb9252) 2019; 54
Yang (10.1016/j.yexmp.2021.104602_bb5500) 2017; 7
Yang (10.1016/j.yexmp.2021.104602_bb0900) 2015; 10
Zhu (10.1016/j.yexmp.2021.104602_bb1095) 2017; 8
Sheng (10.1016/j.yexmp.2021.104602_bb0610) 2019; 200
Liu (10.1016/j.yexmp.2021.104602_bb0445) 2018
Li (10.1016/j.yexmp.2021.104602_bb8259) 2019; 215
Tang (10.1016/j.yexmp.2021.104602_bb0670) 2018; 497
Wang (10.1016/j.yexmp.2021.104602_bb9258) 2017; 8
Li (10.1016/j.yexmp.2021.104602_bb9240) 2018; 22
Meng (10.1016/j.yexmp.2021.104602_bb0510) 2020; 43
An (10.1016/j.yexmp.2021.104602_bb0020) 2020; 242
Chen (10.1016/j.yexmp.2021.104602_bb9249) 2019; 83
Cheng (10.1016/j.yexmp.2021.104602_bb0090) 2019; 12
Xie (10.1016/j.yexmp.2021.104602_bb0830) 2019; 20
Zheng (10.1016/j.yexmp.2021.104602_bb1040) 2019; 19
Shao (10.1016/j.yexmp.2021.104602_bb0595) 2019; 33
Li (10.1016/j.yexmp.2021.104602_bb0360) 2019; 161
Li (10.1016/j.yexmp.2021.104602_bb0350) 2018; 21
Yang (10.1016/j.yexmp.2021.104602_bb0885) 2018; 66
Zuo (10.1016/j.yexmp.2021.104602_bb1120) 2019; 18
Fang (10.1016/j.yexmp.2021.104602_bb0150) 2017; 7
Lin (10.1016/j.yexmp.2021.104602_bb0395) 2002; 62
Lin (10.1016/j.yexmp.2021.104602_bb0390) 2019; 40
Chen (10.1016/j.yexmp.2021.104602_bb9248) 2020
Li (10.1016/j.yexmp.2021.104602_bb9255) 2019; 17
Yang (10.1016/j.yexmp.2021.104602_bb0880) 2020; 111817
Wang (10.1016/j.yexmp.2021.104602_bb0740) 2019; 23
Feng (10.1016/j.yexmp.2021.104602_bb0175) 2017; 623
Ma (10.1016/j.yexmp.2021.104602_bb0500) 2017; 21
Kim (10.1016/j.yexmp.2021.104602_bb0315) 2019; 20
Yu (10.1016/j.yexmp.2021.104602_bb9244) 2018; 22
Shen (10.1016/j.yexmp.2021.104602_bb0605) 2020; 19
Zhang (10.1016/j.yexmp.2021.104602_bb0985) 2016; 20
Tian (10.1016/j.yexmp.2021.104602_bb0690) 2017; 9
Wang (10.1016/j.yexmp.2021.104602_bb0735) 2017; 10
Dai (10.1016/j.yexmp.2021.104602_bb0110) 2020; 12
Abolghasemi (10.1016/j.yexmp.2021.104602_bb0005) 2020; 235
Zhou (10.1016/j.yexmp.2021.104602_bb1075) 2015; 34
Jiang (10.1016/j.yexmp.2021.104602_bb0285) 2019; 9
Huang (10.1016/j.yexmp.2021.104602_bb0260) 2019; 11
Li (10.1016/j.yexmp.2021.104602_bb9251) 2017; 8
Wang (10.1016/j.yexmp.2021.104602_bb0695) 2015; 62
Cheng (10.1016/j.yexmp.2021.104602_bb0080) 2018; 107
Shi (10.1016/j.yexmp.2021.104602_bb0615) 2019; 109
Cheng (10.1016/j.yexmp.2021.104602_bb0085) 2019; 23
Wu (10.1016/j.yexmp.2021.104602_bb0790) 2016; 11
Zhang (10.1016/j.yexmp.2021.104602_bb0975) 2017; 56
Qin (10.1016/j.yexmp.2021.104602_bb0560) 2017; 12
Zhang (10.1016/j.yexmp.2021.104602_bb9237) 2018; 106
Ma (10.1016/j.yexmp.2021.104602_bb0505) 2018; 118
Ye (10.1016/j.yexmp.2021.104602_bb0915) 2016; 7
Miao (10.1016/j.yexmp.2021.104602_bb0515) 2019; 39
Zhen (10.1016/j.yexmp.2021.104602_bb2005) 2017; 36
Fan (10.1016/j.yexmp.2021.104602_bb0145) 2015; 6
Guo (10.1016/j.yexmp.2021.104602_bb0215) 2018; 35
Wang (10.1016/j.yexmp.2021.104602_bb0770) 2020
Zhou (10.1016/j.yexmp.2021.104602_bb1060) 2016; 48
Huang (10.1016/j.yexmp.2021.104602_bb0265) 2020; 43
Song (10.1016/j.yexmp.2021.104602_bb0635) 2017; 108
Ishida (10.1016/j.yexmp.2021.104602_bb0275) 2002; 99
Zhang (10.1016/j.yexmp.2021.104602_bb1005) 2016; 12
Li (10.1016/j.yexmp.2021.104602_bb0340) 2019; 23
Li (10.1016/j.yexmp.2021.104602_bb2040) 2018; 18
Peng (10.1016/j.yexmp.2021.104602_bb0535) 2016; 1
Zeng (10.1016/j.yexmp.2021.104602_bb0955) 2016; 20
Bao (10.1016/j.yexmp.2021.104602_bb0025) 2020; 16
Xie (10.1016/j.yexmp.2021.104602_bb0835) 2017; 8
Yan (10.1016/j.yexmp.2021.104602_bb0870) 2016; 37
Yi (10.1016/j.yexmp.2021.104602_bb0920) 2019; 43
Yu (10.1016/j.yexmp.2021.104602_bb0935) 2020; 24
Zhu (10.1016/j.yexmp.2021.104602_bb1090) 2019; 33
Cui (10.1016/j.yexmp.2021.104602_bb0105) 2018; 39
Su (10.1016/j.yexmp.2021.104602_bb0645) 2017; 10
Wang (10.1016/j.yexmp.2021.104602_bb0725) 2019; 12
Yan (10.1016/j.yexmp.2021.104602_bb9256) 2019; 55
Du (10.1016/j.yexmp.2021.104602_bb0130) 2016; 37
Wang (10.1016/j.yexmp.2021.104602_bb0750) 2017; 37
Chen (10.1016/j.yexmp.2021.104602_bb0075) 2015; 47
Lin (10.1016/j.yexmp.2021.104602_bb0385) 2019; 8
Yu (10.1016/j.yexmp.2021.104602_bb2000) 2019; 10
Ge (10.1016/j.yexmp.2021.104602_bb0190) 2019; 12
Liu (10.1016/j.yexmp.2021.104602_bb0460) 2017; 49
Sun (10.1016/j.yexmp.2021.104602_bb0655) 2017; 16
Xie (10.1016/j.yexmp.2021.104602_bb0840) 2019; 10
Lu (10.1016/j.yexmp.2021.104602_bb0485) 2017; 86
Xie (10.1016/j.yexmp.2021.104602_bb0825) 2020
Zhang (10.1016/j.yexmp.2021.104602_bb0970) 2020; 10
Wang (10.1016/j.yexmp.2021.104602_bb9243) 2016; 15
He (10.1016/j.yexmp.2021.104602_bb0230) 2015; 36
Jiang (10.1016/j.yexmp.2021.104602_bb0290) 2016; 7
Shi (10.1016/j.yexmp.2021.104602_bb0620) 2018; 9
Zhang (10.1016/j.yexmp.2021.104602_bb0995) 2018; 9
Liu (10.1016/j.yexmp.2021.104602_bb0465) 2018; 22
Wang (10.1016/j.yexmp.2021.104602_bb0745) 2015; 5
Wu (10.1016/j.yexmp.2021.104602_bb0780) 2018; 47
Xu (10.1016/j.yexmp.2021.104602_bb0865) 2019; 11
Chen (10.1016/j.yexmp.2021.104602_bb0065) 2019; 120
Gao (10.1016/j.yexmp.2021.104602_bb9257) 2020; 20
Xu (10.1016/j.yexmp.2021.104602_bb0845) 2018; 8
Fang (10.1016/j.yexmp.2021.104602_bb0155) 2016; 22
Zhang (10.1016/j.yexmp.2021.104602_bb2035) 2018; 16
Dasari (10.1016/j.yexmp.2021.104602_bb0115) 2014; 740
Yang (10.1016/j.yexmp.2021.104602_bb0895) 2020; 13
Hu (10.1016/j.yexmp.2021.104602_bb9234) 2020; 19
Zhu (10.1016/j.yexmp.2021.104602_bb1085) 2016; 14
Zhao (10.1016/j.yexmp.2021.104602_bb1020) 2015; 15
Yu (10.1016/j.yexmp.2021.104602_bb9247) 2019; 16
Zhao (10.1016/j.yexmp.2021.104602_bb1025) 2016; 576
Liu (10.1016/j.yexmp.2021.104602_bb9241) 2016; 7
Chen (10.1016/j.yexmp.2021.104602_bb0070) 2019; 17
Fang (10.1016/j.yexmp.2021.104602_bb0170) 2017; 6
Zang (10.1016/j.yexmp.2021.104602_bb0950) 2019; 12
10.1016/j.yexmp.2021.104602_bb5000
Lin (10.1016/j.yexmp.2021.104602_bb0375) 2018; 41
Zhuang (10.1016/j.yexmp.2021.104602_bb1115) 2015; 36
Yin (10.1016/j.yexmp.2021.104602_bb0925) 2015; 34
Chikuda (10.1016/j.yexmp.2021.104602_bb0100) 2020; 12
Liu (10.1016/j.yexmp.2021.104602_bb0430) 2015; 10
Phatak (10.1016/j.yexmp.2021.104602_bb0540) 2016; 35
Luo (10.1016/j.yexmp.2021.104602_bb0490) 2020; 15
Lei (10.1016/j.yexmp.2021.104602_bb0325) 2015; 10
Chen (10.1016/j.yexmp.2021.104602_bb0570) 2016; 7
Liu (10.1016/j.yexmp.2021.104602_bb0425) 2018; 14
Fan (10.1016/j.yexmp.2021.104602_bb0135) 2020; 121
Sun (10.1016/j.yexmp.2021.104602_bb0665) 2018; 51
Holzer (10.1016/j.yexmp.2021.104602_bb0235) 2006; 70
Shindo (10.1016/j.yexmp.2021.104602_bb0625) 2018; 9
Wang (10.1016/j.yexmp.2021.104602_bb9242) 2016; 20
Cao (10.1016/j.yexmp.2021.104602_bb0040) 2017; 93
Xia (10.1016/j.yexmp.2021.104602_bb0815) 2015; 12
Wang (10.1016/j.yexmp.2021.104602_bb0710) 2020; 5
Wu (10.1016/j.yexmp.2021.104602_bb0785) 2019; 115
Wang (10.1016/j.yexmp.2021.104602_bb0765) 2016; 382
Kirave (10.1016/j.yexmp.2021.104602_bb0320) 2020; 11
Li (10.1016/j.yexmp.2021.104602_bb9254) 2019
Peng (10.1016/j.yexmp.2021.104602_bb0530) 2015; 33
Yi (10.1016/j.yexmp.2021.104602_bb2045) 2020; 10
Zhou (10.1016/j.yexmp.2021.104602_bb1055) 2017; 14
Liu (10.1016/j.yexmp.2021.104602_bb9236) 2018; 7
You (10.1016/j.yexmp.2021.104602_bb0930) 2020; 12
Zhu (10.1016/j.yexmp.2021.104602_bb1105) 2016; 35
Yang (10.1016/j.yexmp.2021.104602_bb0890) 2020; 13
Liu (10.1016/j.yexmp.2021.104602_bb0405) 2015; 8
Li (10.1016/j.yexmp.2021.104602_bb0345) 2015; 10
Zhang (10.1016/j.yexmp.2021.104602_bb0965) 2017; 80
Wu (10.1016/j.yexmp.2021.104602_bb0800) 2020; 40
Liu (10.1016/j.yexmp.2021.104602_bb0435) 2018; 39
Tang (10.1016/j.yexmp.2021.104602_bb0680) 2020; 12
Wu (10.1016/j.yexmp.2021.104602_bb0795) 2019; 13
Song (10.1016/j.yexmp.2021.104602_bb0630) 2017; 482
Sui (10.1016/j.yexmp.2021.104602_bb0650) 2015; 13
Sun (10.1016/j.yexmp.2021.104602_bb0120) 2018; 8
Ghasabi (10.1016/j.yexmp.2021.104602_bb0205) 2019; 234
Wang (10.1016/j.yexmp.2021.104602_bb0700) 2018; 9
Dou (10.1016/j.yexmp.2021.104602_bb0125) 2019; 12
Zhu (10.1016/j.yexmp.2021.104602_bb1110) 2016; 11
Liu (10.1016/j.yexmp.2021.104602_bb0415) 2018; 19
Wang (10.1016/j.yexmp.2021.104602_bb0720) 2020; 468
Chi (10.1016/j.yexmp.2021.104602_bb0095) 2018; 29
Xu (10.1016/j.yexmp.2021.104602_bb0855) 2018; 22
Cai (10.1016/j.yexmp.2021.104602_bb0035) 2018; 22
Harel (10.1016/j.yexmp.2021.104602_bb0225) 2015; 22
Zhang (10.1016/j.yexmp.2021.104602_bb1000) 2017; 74
Han (10.1016/j.yexmp.2021.104602_bb0220) 2017; 41
Liu (10.1016/j.yexmp.2021.104602_bb0410) 2019
Tian (10.1016/j.yexmp.2021.104602_bb0685) 2015; 33
Wang (10.1016/j.yexmp.2021.104602_bb0705) 2016; 71
Liu (10.1016/j.yexmp.2021.104602_bb0400) 2017; 16
Wang (10.1016/j.yexmp.2021.104602_bb0715) 2017; 21
Rao (10.1016/j.yexmp.2021.104602_bb0575) 2019; 114
Cao (10.1016/j.yexmp.2021.104602_bb0045) 2018; 51
Wu (10.1016/j.yexmp.2021.104602_bb2010) 2020; 235
An (10.1016/j.yexmp.2021.104602_bb0330) 2020; 31
Wu (10.1016/j.yexmp.2021.104602_bb0805) 2020; 105195
Zhou (10.1016/j.yexmp.2021.104602_bb1050) 2019; 112
Chen (10.1016/j.yexmp.2021.104602_bb0055) 2020; 395
Xu (10.1016/j.yexmp.2021.104602_bb0850) 2018; 8
Ma (10.1016/j.yexmp.2021.104602_bb2015) 2019; 14
Zheng (10.1016/j.yexmp.2021.104602_bb1035) 2017; 36
Qiao (10.1016/j.yexmp.2021.104602_bb0550) 2020; 24
Jin (10.1016/j.yexmp.2021.104602_bb0305) 2018; 38
Liu (10.1016/j.yexmp.2021.104602_bb0440) 2019; 17
Zhang (10.1016/j.yexmp.2021.104602_bb2020) 2018; 47
Xiao (10.1016/j.yexmp.2021.104602_bb0820) 2019; 120
Fan (10.1016/j.yexmp.2021.104602_bb9239) 2017; 88
Qin (10.1016/j.yexmp.2021.1
References_xml – volume: 18
  start-page: 25
  year: 2019
  end-page: 30
  ident: bb1120
  article-title: MiR-126 enhances cisplatin chemosensitivity in hepatocellular carcinoma cells by targeting IRS1
  publication-title: Trop. J. Pharm. Res.
– year: 2019
  ident: bb9254
  article-title: PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2
  publication-title: J. Cell. Biochem.
– volume: 40
  year: 2020
  ident: bb0800
  article-title: miR-492 promotes chemoresistance to CDDP and metastasis by targeting inhibiting DNMT3B and induces stemness in gastric cancer
  publication-title: Biosci. Rep.
– volume: 20
  start-page: 12
  year: 2019
  ident: bb0555
  article-title: Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5
  publication-title: Genome Biol.
– volume: 10
  year: 2020
  ident: bb0970
  article-title: A novel long non-coding RNA, MSTRG. 51053.2 regulates cisplatin resistance by sponging the miR-432-5p in non-small cell lung cancer cells
  publication-title: Front. Oncol.
– volume: 70
  start-page: 1390
  year: 2006
  end-page: 1394
  ident: bb0235
  article-title: Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin
  publication-title: Mol. Pharmacol.
– volume: 482
  start-page: 22
  year: 2017
  end-page: 27
  ident: bb0630
  article-title: miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 6
  start-page: 26457
  year: 2015
  ident: bb0860
  article-title: MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1
  publication-title: Oncotarget.
– volume: 54
  start-page: 239
  year: 2019
  end-page: 248
  ident: bb9252
  article-title: LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA-30b/autophagy-related gene 5 axis in gastric cancer
  publication-title: Int. J. Oncol.
– volume: 8
  start-page: 22003
  year: 2017
  ident: bb0835
  article-title: MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1
  publication-title: Oncotarget.
– year: 2018
  ident: bb0445
  article-title: miR-451 selectively increases sensitivity to cisplatin in ERCC1-high non-small cell lung cancer cells
  publication-title: J. Cell. Biochem.
– volume: 37
  start-page: 1261
  year: 2016
  end-page: 1269
  ident: bb0130
  article-title: miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB
  publication-title: Tumor Biol.
– volume: 11
  year: 2016
  ident: bb1110
  article-title: MiR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells
  publication-title: PLoS One
– volume: 16
  start-page: 30
  year: 2016
  ident: bb0355
  article-title: MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin
  publication-title: Cancer Cell Int.
– volume: 22
  start-page: 1328
  year: 2015
  end-page: 1340
  ident: bb0225
  article-title: Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth
  publication-title: Cell Death Differ.
– volume: 17
  start-page: 92
  year: 2019
  end-page: 101
  ident: bb9255
  article-title: lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143/FOSL2-signaling pathway in ovarian cancer
  publication-title: Mol. Ther. Nucleic Acids
– volume: 8
  start-page: 61
  year: 2018
  ident: bb0845
  article-title: TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2
  publication-title: Cell Biosci.
– volume: 11
  start-page: 91
  year: 2020
  end-page: 102
  ident: bb0050
  article-title: MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1
  publication-title: Bioengineered.
– volume: 107
  start-page: 338
  year: 2018
  end-page: 346
  ident: bb0675
  article-title: Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer
  publication-title: Biomed. Pharmacother.
– volume: 86
  start-page: 450
  year: 2017
  end-page: 456
  ident: bb0485
  article-title: MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp
  publication-title: Biomed. Pharmacother.
– volume: 41
  start-page: 2050
  year: 2018
  end-page: 2058
  ident: bb0375
  article-title: miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells
  publication-title: Int. J. Mol. Med.
– volume: 23
  start-page: 4220
  year: 2019
  end-page: 4225
  ident: bb0590
  article-title: Long noncoding RNA OR3A4 promotes cisplatin resistance of non-small cell lung cancer by upregulating CDK1
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 6
  start-page: 2897
  year: 2017
  end-page: 2908
  ident: bb0170
  article-title: LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression
  publication-title: Cancer Med.
– volume: 43
  start-page: 1169
  year: 2020
  end-page: 1186
  ident: bb0510
  article-title: MicroRNA-22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway
  publication-title: Oncol. Rep.
– volume: 16
  start-page: 2100
  year: 2017
  end-page: 2107
  ident: bb0655
  article-title: LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis
  publication-title: Cell Cycle
– volume: 120
  start-page: 9656
  year: 2019
  end-page: 9666
  ident: bb0640
  article-title: Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p
  publication-title: J. Cell. Biochem.
– volume: 10
  start-page: 1039
  year: 2019
  ident: bb0840
  article-title: MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells
  publication-title: J. Cancer
– volume: 24
  start-page: 200
  year: 2020
  end-page: 212
  ident: bb0550
  article-title: LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 15
  year: 2016
  ident: bb9243
  article-title: MiR-125b functions as a tumor suppressor and enhances chemosensitivity to cisplatin in osteosarcoma
  publication-title: Technol. Cancer Res. Treat.
– volume: 8
  start-page: 3314
  year: 2016
  ident: bb0450
  article-title: Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patients
  publication-title: J. Thorac. Disease.
– volume: 12
  start-page: 856
  year: 2020
  ident: bb0100
  article-title: CD44s induces miR-629-3p expression in association with cisplatin resistance in head and neck cancer cells
  publication-title: Cancers (Basel)
– volume: 114
  start-page: 108662
  year: 2019
  ident: bb0575
  article-title: MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9
  publication-title: Biomed. Pharmacother.
– volume: 22
  start-page: 4440
  year: 2018
  end-page: 4447
  ident: bb0855
  article-title: LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 55
  start-page: 988
  year: 2019
  end-page: 1002
  ident: bb9256
  article-title: LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR-9-5p and regulating SPAG9 expression
  publication-title: Int. J. Oncol.
– volume: 33
  start-page: 591
  year: 2015
  end-page: 598
  ident: bb1010
  article-title: Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer
  publication-title: Oncol. Rep.
– volume: 19
  start-page: 250
  year: 2019
  ident: bb1040
  article-title: miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway
  publication-title: Cancer Cell Int.
– volume: 9
  start-page: 2105
  year: 2018
  ident: bb0995
  article-title: The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin
  publication-title: Oncotarget.
– volume: 40
  start-page: 883
  year: 2019
  end-page: 892
  ident: bb0390
  article-title: miR-338-5p inhibits cell proliferation, colony formation, migration and cisplatin resistance in esophageal squamous cancer cells by targeting FERMT2
  publication-title: Carcinogenesis.
– reference: Yu Z., Cao W., Ren Y., Zhang Q., Liu J., ATPase copper transporter A, negatively regulated by miR-148a-3p, contributes to cisplatin resistance in breast cancer cells. Clin. Transl. Med.
– volume: 23
  start-page: 1093
  year: 2019
  end-page: 1101
  ident: bb0180
  article-title: LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 34
  start-page: 368
  year: 2015
  end-page: 374
  ident: bb0925
  article-title: miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy
  publication-title: Oncol. Rep.
– volume: 21
  start-page: 2650
  year: 2017
  end-page: 2658
  ident: bb0945
  article-title: MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 10
  year: 2015
  ident: bb0900
  article-title: Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small cell lung cancer to cisplatin
  publication-title: PLoS One
– volume: 28
  start-page: 65
  year: 2019
  end-page: 73
  ident: bb0420
  article-title: Overexpression of the long non-coding RNA FOXD2-AS1 promotes cisplatin resistance in esophageal squamous cell carcinoma through the miR-195-Akt-mTOR axis
  publication-title: Oncol. Res. Featur. Preclin. Clin. Cancer Therap.
– volume: 15
  start-page: 731
  year: 2015
  ident: bb1020
  article-title: The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer
  publication-title: BMC Cancer
– volume: 382
  start-page: 137
  year: 2016
  end-page: 146
  ident: bb0765
  article-title: Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis
  publication-title: Cancer Lett.
– volume: 16
  start-page: 827
  year: 2020
  ident: bb0025
  article-title: Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition
  publication-title: Int. J. Biol. Sci.
– volume: 12
  start-page: 233
  year: 2020
  ident: bb0930
  article-title: miR106a promotes the growth of transplanted breast cancer and decreases the sensitivity of transplanted tumors to Cisplatin
  publication-title: Cancer Manag. Res.
– volume: 22
  start-page: 4879
  year: 2018
  end-page: 4887
  ident: bb0035
  article-title: LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 11
  start-page: 945
  year: 2016
  end-page: 952
  ident: bb0790
  article-title: miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9
  publication-title: Oncol. Lett.
– volume: 39
  start-page: 1649
  year: 2018
  end-page: 1657
  ident: bb0105
  article-title: miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8
  publication-title: Oncol. Rep.
– volume: 12
  start-page: 11057
  year: 2019
  ident: bb0090
  article-title: Knockdown Of lncRNA NCK-AS1 Regulates Cisplatin Resistance Through Modulating miR-137 In Osteosarcoma Cells
  publication-title: OncoTargets Ther.
– volume: 80
  start-page: 973
  year: 2017
  end-page: 984
  ident: bb0965
  article-title: miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1
  publication-title: Cancer Chemother. Pharmacol.
– volume: 83
  start-page: 921
  year: 2019
  end-page: 931
  ident: bb9249
  article-title: The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis
  publication-title: Cancer Chemother. Pharmacol.
– volume: 7
  start-page: 43337
  year: 2016
  ident: bb0290
  article-title: NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells
  publication-title: Oncotarget.
– volume: 7
  start-page: 43109
  year: 2017
  ident: bb5500
  article-title: miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer
  publication-title: Scientific reports
– volume: 17
  start-page: 1664
  year: 2019
  end-page: 1674
  ident: bb0070
  article-title: MicroRNA-504 modulates osteosarcoma cell chemoresistance to cisplatin by targeting p53
  publication-title: Oncol. Lett.
– volume: 16
  start-page: 257
  year: 2019
  end-page: 271
  ident: bb9247
  article-title: lncRNA TUG1 promotes cisplatin resistance by regulating CCND2 via epigenetically silencing miR-194-5p in bladder cancer
  publication-title: Mol. Ther. Nucleic Acids
– volume: 10
  year: 2015
  ident: bb0430
  article-title: The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma
  publication-title: PLoS One
– volume: 22
  start-page: 7653
  year: 2018
  end-page: 7659
  ident: bb0730
  article-title: MALAT1 promotes cisplatin resistance in cervical cancer by activating the PI3K/AKT pathway
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 5
  start-page: 17618
  year: 2015
  ident: bb0745
  article-title: MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC
  publication-title: Sci. Rep.
– volume: 46
  start-page: 831
  year: 2020
  end-page: 838
  ident: bb0495
  article-title: MicroRNA-31 weakens cisplatin resistance of medulloblastoma cells via NF-κB and PI3K/AKT pathways
  publication-title: BioFactors.
– volume: 29
  start-page: 1438
  year: 2018
  end-page: 1448
  ident: bb0095
  article-title: HOXD-AS1 exerts oncogenic functions and promotes chemoresistance in cisplatin-resistant cervical cancer cells
  publication-title: Hum. Gene Ther.
– volume: 591
  start-page: 636
  year: 2017
  end-page: 645
  ident: bb0210
  article-title: Suppression of EIF 4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells
  publication-title: FEBS Lett.
– volume: 9
  start-page: 1127
  year: 2017
  ident: bb0690
  article-title: MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2
  publication-title: Am. J. Transl. Res.
– volume: 1
  start-page: 1
  year: 2016
  end-page: 9
  ident: bb0535
  article-title: The role of MicroRNAs in human cancer
  publication-title: Signal Transd. Target. Ther.
– volume: 19
  start-page: 1797
  year: 2020
  end-page: 1805
  ident: bb1080
  article-title: MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1
  publication-title: Exp. Therap. Med.
– volume: 19
  start-page: 534
  year: 2018
  end-page: 542
  ident: bb0415
  article-title: LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway
  publication-title: Cancer Biol. Ther.
– volume: 11
  start-page: 1157
  year: 2020
  ident: bb0320
  article-title: Exosome mediated miR-155 delivery confers cisplatin chemoresistance in oral cancer cells via epithelial-mesenchymal transition
  publication-title: Oncotarget.
– volume: 9
  start-page: 1
  year: 2018
  end-page: 17
  ident: bb0760
  article-title: miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1
  publication-title: Cell Death Dis.
– volume: 16
  start-page: 1
  year: 2018
  end-page: 11
  ident: bb2035
  article-title: KLF4, a miR-32-5p targeted gene, promotes cisplatin-induced apoptosis by upregulating BIK expression in prostate cancer
  publication-title: Cell Comm. Signal.
– volume: 13
  start-page: 2783
  year: 2020
  ident: bb0905
  article-title: Long Non-Coding RNA SPRY4-IT1 Reverses Cisplatin Resistance by Downregulating MPZL-1 via Suppressing EMT in NSCLC
  publication-title: OncoTargets Ther.
– volume: 395
  start-page: 507
  year: 2020
  end-page: 513
  ident: bb0055
  article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
  publication-title: Lancet
– volume: 24
  start-page: 1688
  year: 2020
  end-page: 1696
  ident: bb0935
  article-title: MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 8
  start-page: 2558
  year: 2017
  ident: bb9258
  article-title: Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma
  publication-title: Oncotarget
– volume: 47
  start-page: 1603
  year: 2015
  end-page: 1611
  ident: bb0075
  article-title: miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2
  publication-title: Int. J. Oncol.
– volume: 74
  start-page: 2613
  year: 2017
  end-page: 2625
  ident: bb1000
  article-title: Emerging role of MicroRNAs in mTOR signaling
  publication-title: Cell. Mol. Life Sci.
– volume: 8
  start-page: 1
  year: 2018
  end-page: 9
  ident: bb0120
  article-title: MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway
  publication-title: Sci. Rep.
– volume: 38
  start-page: 564
  year: 2019
  end-page: 580
  ident: bb9245
  article-title: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer
  publication-title: Oncogene
– volume: 33
  start-page: 264
  year: 2019
  end-page: 274
  ident: bb0595
  article-title: Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer
  publication-title: FASEB J.
– volume: 12
  start-page: 9513
  year: 2019
  ident: bb0725
  article-title: miR-152-3p sensitizes glioblastoma cells towards cisplatin via regulation of SOS1
  publication-title: OncoTargets Ther.
– volume: 37
  start-page: 2720
  year: 2017
  end-page: 2726
  ident: bb0750
  article-title: miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer
  publication-title: Oncol. Rep.
– volume: 88
  start-page: 507
  year: 2017
  end-page: 514
  ident: bb9239
  article-title: MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM)
  publication-title: Biomed. Pharmacother.
– volume: 12
  start-page: 6105
  year: 2019
  ident: bb0190
  article-title: lncRNA FOXD2-AS1 confers cisplatin resistance of non-small-cell lung cancer via regulation of miR185-5p–SIX1 axis
  publication-title: OncoTargets Ther.
– volume: 8
  start-page: 39154
  year: 2017 Jun 13
  end-page: 39166
  ident: bb1095
  article-title: IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells
  publication-title: Oncotarget.
– volume: 22
  start-page: 1249
  year: 2018
  end-page: 1257
  ident: bb0465
  article-title: Down-regulation of miR-377 contributes to cisplatin resistance by targeting XIAP in osteosarcoma
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– year: 2020
  ident: bb0825
  article-title: Serum miR-27a is a Biomarker for Prognosis of Non-Small Cell Lung Cancer Patients Receiving Chemotherapy
– volume: 9
  start-page: 555
  year: 2018
  ident: bb0620
  article-title: miR-205-5p mediated downregulation of PTEN contributes to cisplatin resistance in C13K human ovarian cancer cells
  publication-title: Front. Genet.
– volume: 16
  start-page: 4107
  year: 2017
  end-page: 4112
  ident: bb0400
  article-title: Long non-coding RNA AK001796 contributes to cisplatin resistance of non-small cell lung cancer
  publication-title: Mol. Med. Rep.
– volume: 22
  start-page: 299
  year: 2018
  end-page: 306
  ident: bb9240
  article-title: MiR-205 enhances cisplatin sensitivity of glioma cells by targeting E2F1
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 13
  start-page: 109
  year: 2020
  ident: bb0895
  article-title: miR-1269b drives cisplatin resistance of human non-small cell lung cancer via modulating the PTEN/PI3K/AKT signaling pathway
  publication-title: OncoTargets Ther.
– volume: 9
  start-page: 1
  year: 2018
  end-page: 16
  ident: bb0990
  article-title: LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling
  publication-title: Cell Death Dis.
– volume: 12
  start-page: 4530
  year: 2015
  end-page: 4537
  ident: bb0815
  article-title: Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway
  publication-title: Mol. Med. Rep.
– volume: 20
  start-page: 3540
  year: 2019
  ident: bb0315
  article-title: MiR-1208 Increases the Sensitivity to Cisplatin by Targeting TBCK in Renal Cancer Cells
  publication-title: Int. J. Mol. Sci.
– volume: 8
  start-page: 1
  year: 2018
  end-page: 11
  ident: bb0850
  article-title: TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2
  publication-title: Cell Biosci.
– volume: 13
  start-page: 2887
  year: 2020
  ident: bb0890
  article-title: miR-34c targets MET to improve the anti-tumor effect of cisplatin on Ovarian Cancer
  publication-title: OncoTargets Ther.
– volume: 17
  start-page: 1453
  year: 2019
  end-page: 1460
  ident: bb0440
  article-title: miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases
  publication-title: Oncol. Lett.
– volume: 469
  start-page: 266
  year: 2020
  end-page: 276
  ident: bb0585
  article-title: MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2
  publication-title: Cancer Lett.
– volume: 64
  start-page: 706
  year: 2012
  end-page: 721
  ident: bb0600
  article-title: Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes
  publication-title: Pharmacol. Rev.
– volume: 36
  start-page: 275
  year: 2017
  end-page: 285
  ident: bb2005
  article-title: miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin
  publication-title: Oncogene
– volume: 14
  start-page: 745
  year: 2018
  ident: bb0425
  article-title: miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2
  publication-title: Arch. Med. Sci.
– volume: 28
  start-page: 204
  year: 2020
  end-page: 211
  ident: bb1065
  article-title: Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling
  publication-title: J. Drug Target.
– volume: 24
  start-page: 208
  year: 2017
  end-page: 214
  ident: bb0475
  article-title: MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1
  publication-title: Cancer Gene Ther.
– volume: 107
  start-page: 2620
  year: 2018
  end-page: 2629
  ident: bb0080
  article-title: Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a
  publication-title: Int. J. Biol. Macromol.
– volume: 235
  start-page: 1247
  year: 2020
  end-page: 1258
  ident: bb2010
  article-title: microRNA‐10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer
  publication-title: J. Cell. Physiol.
– volume: 39
  year: 2019
  ident: bb0310
  article-title: Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α
  publication-title: Biosci. Rep.
– volume: 23
  start-page: 7256
  year: 2019
  end-page: 7265
  ident: bb0085
  article-title: Long non-coding RNA ROR regulated ABCB1 to induce cisplatin resistance in osteosarcoma by sponging miR-153-3p
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 2019
  year: 2019
  ident: bb0755
  article-title: LncRNA HOXA11-AS promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by suppression of miR-214-3p expression
  publication-title: Biomed. Res. Int.
– volume: 51
  start-page: 1148
  year: 2019
  end-page: 1157
  ident: bb0455
  article-title: LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer
  publication-title: Acta Biochim. Biophys. Sin.
– volume: 7
  start-page: 4598
  year: 2018
  end-page: 4609
  ident: bb9236
  article-title: MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
  publication-title: Cancer Med.
– volume: 22
  start-page: 108
  year: 2015
  end-page: 114
  ident: bb1030
  article-title: miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells
  publication-title: Cancer Gene Ther.
– volume: 572
  start-page: 116
  year: 2015
  end-page: 122
  ident: bb0525
  article-title: Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1
  publication-title: Gene.
– volume: 242
  start-page: 117162
  year: 2020
  ident: bb0020
  article-title: MiR-21 modulates the polarization of macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer
  publication-title: Life Sci.
– volume: 14
  start-page: 8121
  year: 2019
  ident: bb2015
  article-title: Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy
  publication-title: Int. J. Nanomed.
– volume: 468
  start-page: 14
  year: 2020 Jan 1
  end-page: 26
  ident: bb0720
  article-title: SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression
  publication-title: Cancer Lett.
– volume: 31
  start-page: 473
  year: 2020
  end-page: 482
  ident: bb0330
  article-title: Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axis
  publication-title: Anti-Cancer Drugs
– volume: 22
  start-page: 3506
  year: 2016
  ident: bb0155
  article-title: Long non-coding RNA (LncRNA) urothelial carcinoma associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b
  publication-title: Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.
– volume: 21
  start-page: 4064
  year: 2017
  end-page: 4070
  ident: bb0715
  article-title: BCAR4 increase cisplatin resistance and predicted poor survival in gastric cancer patients
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 43
  start-page: 12
  year: 2019
  end-page: 21
  ident: bb0920
  article-title: miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1
  publication-title: Cell Biol. Int.
– volume: 576
  start-page: 828
  year: 2016
  end-page: 833
  ident: bb1025
  article-title: MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin
  publication-title: Gene.
– volume: 8
  start-page: 20565
  year: 2015
  ident: bb0405
  article-title: Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways
  publication-title: Int. J. Clin. Exp. Med.
– volume: 521
  start-page: 271
  year: 2020
  end-page: 278
  ident: bb0370
  article-title: Up-regulated lnc-lung cancer associated transcript 1 enhances cell migration and invasion in breast cancer progression
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 38
  year: 2018 Aug 31
  ident: bb0300
  article-title: STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance
  publication-title: Biosci. Rep.
– volume: 62
  start-page: 1154
  year: 2002
  end-page: 1159
  ident: bb0395
  article-title: The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae
  publication-title: Mol. Pharmacol.
– volume: 7
  start-page: 53254
  year: 2016
  ident: bb1015
  article-title: MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2
  publication-title: Oncotarget.
– volume: 26
  start-page: 632
  year: 2015
  end-page: 640
  ident: bb9253
  article-title: Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression
  publication-title: Anti-Cancer Drugs
– volume: 49
  start-page: 808
  year: 2017
  end-page: 816
  ident: bb0460
  article-title: Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma
  publication-title: Acta Biochim. Biophys. Sin.
– volume: 51
  start-page: 456
  year: 2018
  ident: bb0045
  article-title: MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition
  publication-title: BMB Rep.
– volume: 10
  start-page: 1278
  year: 2019
  ident: bb2000
  article-title: Targeted inhibition of miR-221/222 promoted cell sensitivity to cisplatin in triple negative breast cancer
  publication-title: Front. Genet.
– volume: 51
  start-page: 129
  year: 2018
  end-page: 141
  ident: bb0295
  article-title: Recovery of miR-139-5p in ovarian cancer reverses cisplatin resistance by targeting C-Jun
  publication-title: Cell. Physiol. Biochem.
– volume: 43
  start-page: 1906
  year: 2020
  end-page: 1914
  ident: bb0265
  article-title: miR-10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway
  publication-title: Oncol. Rep.
– volume: 71
  start-page: 598
  year: 2016
  end-page: 602
  ident: bb0705
  article-title: Knockdown of long noncoding RNA urothelial cancer-associated 1 enhances cisplatin chemosensitivity in tongue squamous cell carcinoma cells
  publication-title: Die Pharm. Int. J. Pharm. Sci.
– volume: 497
  start-page: 827
  year: 2018
  end-page: 834
  ident: bb0670
  article-title: miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 121
  start-page: 1675
  year: 2020
  end-page: 1689
  ident: bb0135
  article-title: MiR-1827 functions as a tumor suppressor in lung adenocarcinoma by targeting MYC and FAM83F
  publication-title: J. Cell. Biochem.
– volume: 66
  start-page: 369
  year: 2018
  end-page: 377
  ident: bb0885
  article-title: MiR-29a-mediated CD133 expression contributes to cisplatin resistance in CD133+ glioblastoma stem cells
  publication-title: J. Mol. Neurosci.
– volume: 99
  start-page: 14298
  year: 2002
  end-page: 14302
  ident: bb0275
  article-title: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
  publication-title: Proc. Natl. Acad. Sci.
– volume: 38
  year: 2018
  ident: bb0255
  article-title: Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma
  publication-title: Biosci. Rep.
– volume: 23
  start-page: 4185
  year: 2019
  end-page: 4191
  ident: bb0340
  article-title: LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 7
  start-page: 1
  year: 2018
  end-page: 13
  ident: bb0030
  article-title: Dysregulation of the MiR-449b target TGFBI alters the TGFβ pathway to induce cisplatin resistance in nasopharyngeal carcinoma
  publication-title: Oncogenesis.
– volume: 121
  start-page: 1353
  year: 2020 Feb
  end-page: 1361
  ident: bb0335
  article-title: PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2
  publication-title: J. Cell. Biochem.
– volume: 11
  start-page: 12328
  year: 2019
  ident: bb0480
  article-title: Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis
  publication-title: Aging (Albany NY)
– volume: 10
  year: 2015
  ident: bb0325
  article-title: miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells
  publication-title: PLoS One
– volume: 23
  start-page: 5229
  year: 2019
  end-page: 5234
  ident: bb0740
  article-title: Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 14
  start-page: 1742
  year: 2016
  end-page: 1750
  ident: bb1085
  article-title: miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD
  publication-title: Mol. Med. Rep.
– volume: 7
  start-page: 1
  year: 2017
  end-page: 11
  ident: bb0150
  article-title: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway
  publication-title: Sci. Rep.
– volume: 105195
  year: 2020
  ident: bb0805
  article-title: PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma
  publication-title: Pharmacol. Res.
– volume: 93
  start-page: 570
  year: 2017
  end-page: 579
  ident: bb0040
  article-title: GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis
  publication-title: Biomed. Pharmacother.
– volume: 8
  start-page: 39154
  year: 2017
  ident: bb1100
  article-title: IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells
  publication-title: Oncotarget.
– volume: 18
  start-page: 404
  year: 2018
  ident: bb2040
  article-title: MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells
  publication-title: BMC cancer
– volume: 234
  start-page: 22581
  year: 2019
  end-page: 22592
  ident: bb0205
  article-title: The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration
  publication-title: J. Cell. Physiol.
– volume: 47
  start-page: 1432
  year: 2018
  end-page: 1441
  ident: bb2020
  article-title: Knockdown of MiR-20a enhances sensitivity of colorectal Cancer cells to cisplatin by increasing ASK1 expression
  publication-title: Cell. Physiol. Biochem.
– volume: 12
  start-page: 1437
  year: 2016
  ident: bb1005
  article-title: MiR-99a and MiR-491 regulate cisplatin resistance in human gastric cancer cells by targeting CAPNS1
  publication-title: Int. J. Biol. Sci.
– volume: 13
  start-page: 99
  year: 2019
  end-page: 112
  ident: bb0795
  article-title: NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis
  publication-title: J. Cell Commun. Signal.
– volume: 11
  start-page: 2551
  year: 2019
  ident: bb0865
  article-title: MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway
  publication-title: Aging (Albany NY)
– volume: 21
  start-page: 135
  year: 2018
  end-page: 144
  ident: bb0350
  article-title: miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal
  publication-title: Cancer Biom.
– volume: 21
  start-page: 2626
  year: 2017
  end-page: 2634
  ident: bb0500
  article-title: Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53-p66shc pathway
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 56
  start-page: 2022
  year: 2017
  end-page: 2034
  ident: bb0975
  article-title: Upregulated miR-132 in Lgr5+ gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway
  publication-title: Mol. Carcinog.
– volume: 120
  start-page: 2940
  year: 2019
  end-page: 2953
  ident: bb0820
  article-title: MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy
  publication-title: J. Cell. Biochem.
– volume: 20
  start-page: 3355
  year: 2019
  end-page: 3362
  ident: bb0830
  article-title: Cisplatin decreases cyclin D2 expression via upregulating miR-93 to inhibit lung adenocarcinoma cell growth
  publication-title: Mol. Med. Rep.
– volume: 9
  start-page: 402
  year: 2018
  ident: bb0520
  article-title: Overview of MicroRNA biogenesis, mechanisms of actions, and circulation
  publication-title: Front. Endocrinol. (Lausanne)
– volume: 47
  start-page: 2077
  year: 2018
  end-page: 2087
  ident: bb0780
  article-title: miR-100 reverses cisplatin resistance in breast Cancer by suppressing HAX-1
  publication-title: Cell. Physiol. Biochem.
– volume: 33
  start-page: 981
  year: 2015
  end-page: 989
  ident: bb0685
  article-title: miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin
  publication-title: Oncol. Rep.
– volume: 39
  year: 2017
  ident: bb2025
  article-title: Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells
  publication-title: Tumor Biol.
– volume: 120
  start-page: 243
  year: 2019
  end-page: 252
  ident: bb0065
  article-title: The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer
  publication-title: J. Cell. Biochem.
– volume: 7
  start-page: 24510
  year: 2016
  ident: bb0570
  article-title: miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET
  publication-title: Oncotarget
– volume: 18
  start-page: 974
  year: 2017
  end-page: 983
  ident: bb0250
  article-title: LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4
  publication-title: Cancer Biol. Ther.
– volume: 10
  year: 2015
  ident: bb0345
  article-title: MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells
  publication-title: PLoS One
– volume: 161
  start-page: 98
  year: 2019
  end-page: 112
  ident: bb0360
  article-title: miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes
  publication-title: Biochem. Pharmacol.
– volume: 623
  start-page: 20
  year: 2017
  end-page: 30
  ident: bb0175
  article-title: Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin
  publication-title: Arch. Biochem. Biophys.
– volume: 36
  start-page: 2737
  year: 2015
  end-page: 2745
  ident: bb1115
  article-title: Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2
  publication-title: Tumor Biol.
– year: 2020
  ident: bb9248
  article-title: LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling
  publication-title: J. Biochem. Mol. Toxicol.
– volume: 11
  start-page: 2138
  year: 2019
  ident: bb0260
  article-title: MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway
  publication-title: Aging (Albany NY)
– volume: 7
  start-page: 86446
  year: 2016
  ident: bb9241
  article-title: Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells
  publication-title: Oncotarget
– volume: 39
  start-page: 1477
  year: 2017
  end-page: 1484
  ident: bb0660
  article-title: Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells
  publication-title: Biotechnol. Lett.
– volume: 37
  start-page: 2565
  year: 2016
  end-page: 2573
  ident: bb0580
  article-title: Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells
  publication-title: Tumor Biol.
– volume: 215
  start-page: 931
  year: 2019
  end-page: 938
  ident: bb8259
  article-title: Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro
  publication-title: Pathology-Research and Practice
– volume: 8
  start-page: 97476
  year: 2017
  ident: bb9251
  article-title: Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma
  publication-title: Oncotarget
– volume: 15
  start-page: e0223035
  year: 2020
  ident: bb0490
  article-title: LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1
  publication-title: PLoS One.
– volume: 37
  start-page: 4509
  year: 2016
  end-page: 4515
  ident: bb0910
  article-title: Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer
  publication-title: Tumor Biol.
– volume: 36
  start-page: 53
  year: 2017
  ident: bb1035
  article-title: Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells
  publication-title: J. Exp. Clin. Cancer Res.
– volume: 9
  start-page: 24457
  year: 2018
  ident: bb0625
  article-title: Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer
  publication-title: Oncotarget.
– volume: 19
  start-page: 193
  year: 2020
  end-page: 206
  ident: bb9234
  article-title: miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway
  publication-title: Cell Cycle
– volume: 35
  start-page: 204
  year: 2018
  end-page: 221
  ident: bb0215
  article-title: The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells
  publication-title: EBioMedicine.
– volume: 70
  start-page: 203
  year: 2018
  end-page: 213
  ident: bb0015
  article-title: MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway
  publication-title: Cytotechnology
– volume: 9
  start-page: 7501
  year: 2018
  ident: bb0700
  article-title: MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer
  publication-title: Oncotarget.
– volume: 12
  year: 2019
  ident: bb0125
  article-title: EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
  publication-title: OncoTargets Ther.
– volume: 20
  start-page: 1
  year: 2020
  end-page: 16
  ident: bb9257
  article-title: Inhibition of ZEB1–AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation
  publication-title: Cancer Cell Int.
– volume: 109
  start-page: 902
  year: 2019
  end-page: 909
  ident: bb0615
  article-title: MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells
  publication-title: Biomed. Pharmacother.
– volume: 12
  start-page: 3721
  year: 2017
  ident: bb0560
  article-title: Cisplatin-resistant lung cancer cell–derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100–5p-dependent manner
  publication-title: Int. J. Nanomedicine
– volume: 200
  start-page: 45
  year: 2019
  end-page: 52
  ident: bb0610
  article-title: Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells
  publication-title: Clin. Exp. Immunol.
– volume: 36
  start-page: 2065
  year: 2015
  end-page: 2075
  ident: bb0230
  article-title: MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1
  publication-title: Tumor Biol.
– volume: 16
  start-page: 2946
  year: 2017
  end-page: 2952
  ident: bb9259
  article-title: Long non-coding RNA MEG3 contributes to cisplatin-induced apoptosis via inhibition of autophagy in human glioma cells
  publication-title: Mol. Med. Rep.
– volume: 22
  start-page: 5867
  year: 2018
  end-page: 5873
  ident: bb9244
  article-title: MiR-100 up-regulation enhanced cell autophagy and apoptosis induced by cisplatin in osteosarcoma by targeting mTOR
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 362
  start-page: 183
  year: 2015
  end-page: 191
  ident: bb0140
  article-title: miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1
  publication-title: Cancer Lett.
– volume: 235
  start-page: 5059
  year: 2020 Jun
  end-page: 5071
  ident: bb0005
  article-title: Critical roles of long noncoding RNAs in breast cancer
  publication-title: J. Cell. Physiol.
– volume: 38
  year: 2018
  ident: bb0305
  article-title: STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance
  publication-title: Biosci. Rep.
– volume: 12
  start-page: 2001
  year: 2020
  ident: bb0680
  article-title: LncRNA-ATB Promotes Cisplatin Resistance in Lung Adenocarcinoma Cells by Targeting the miR-200a/β-Catenin Pathway
  publication-title: Cancer Manag. Res.
– volume: 41
  start-page: 973
  year: 2017
  end-page: 986
  ident: bb0220
  article-title: A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells
  publication-title: Cell. Physiol. Biochem.
– volume: 62
  start-page: 432
  year: 2015
  end-page: 438
  ident: bb0695
  article-title: Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells
  publication-title: Neoplasma.
– volume: 14
  start-page: 7986
  year: 2017
  end-page: 7992
  ident: bb1055
  article-title: Knockdown of long non-coding RNA HOTAIR sensitizes hepatocellular carcinoma cell to cisplatin by suppressing the STAT3/ABCB1 signaling pathway
  publication-title: Oncol. Lett.
– volume: 22
  start-page: 5490
  year: 2018
  end-page: 5498
  ident: bb2030
  article-title: The increase of miR-27a affects the role of cisplatin on proliferation and migration capacities of liver cancer cells
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 19
  start-page: 533
  year: 2020
  end-page: 541
  ident: bb0270
  article-title: Knockdown of lncRNA MIAT inhibits proliferation and cisplatin resistance in non-small cell lung cancer cells by increasing miR-184 expression
  publication-title: Oncol Lett.
– volume: 19
  start-page: 1
  year: 2020
  end-page: 17
  ident: bb0960
  article-title: CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
  publication-title: Mol. Cancer
– volume: 35
  start-page: 323
  year: 2016
  end-page: 332
  ident: bb1105
  article-title: miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin
  publication-title: Oncogene.
– volume: 12
  start-page: 1929
  year: 2020
  ident: bb0110
  article-title: LncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K/AKT pathway
  publication-title: Cancer Manag. Res.
– volume: 12
  start-page: 7551
  year: 2019
  ident: bb0950
  article-title: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
  publication-title: OncoTargets Ther.
– volume: 10
  start-page: 280
  year: 2019
  ident: bb0365
  article-title: Long non-coding RNA DLEU1 promotes cell proliferation, invasion and confers cisplatin resistance in bladder cancer by regulating the miR-99b/HS3ST3B1 axis
  publication-title: Front. Genet.
– volume: 39
  start-page: 1631
  year: 2018
  end-page: 1639
  ident: bb0435
  article-title: miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway
  publication-title: Oncol. Rep.
– volume: 5
  start-page: 100103
  year: 2020
  ident: bb0710
  article-title: MicroRNA-135a promotes proliferation, migration, invasion and induces chemoresistance of endometrial cancer cells
  publication-title: Eur. J. Obstetr. Gynecol. Reprod. Biol. X.
– volume: 19
  start-page: 630
  year: 2020
  end-page: 638
  ident: bb0940
  article-title: MicroRNA-138 inhibits tumor growth and enhances chemosensitivity in human cervical cancer by targeting H2AX
  publication-title: Exp. Therap. Med.
– volume: 10
  start-page: 5137
  year: 2017
  ident: bb0735
  article-title: LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis
  publication-title: OncoTargets Ther.
– volume: 33
  start-page: 382
  year: 2019
  ident: bb1090
  article-title: miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5
  publication-title: J. Biomed. Res.
– volume: 9
  start-page: 1354
  year: 2019
  end-page: 1366
  ident: bb0285
  article-title: Emerging roles of lncRNA in cancer and therapeutic opportunities
  publication-title: Am. J. Cancer Res.
– volume: 20
  start-page: 2271
  year: 2016
  end-page: 2277
  ident: bb0985
  article-title: GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 20
  start-page: 1733
  year: 2016
  end-page: 1739
  ident: bb9242
  article-title: MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT)
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 6
  start-page: 26093
  year: 2016
  ident: bb1045
  article-title: The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in high-grade serous ovarian cancer
  publication-title: Sci. Rep.
– volume: 48
  start-page: 1737
  year: 2016
  end-page: 1748
  ident: bb1060
  article-title: miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells
  publication-title: Int. J. Oncol.
– volume: 19
  start-page: 375
  year: 2020
  end-page: 383
  ident: bb0605
  article-title: miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC
  publication-title: Exp. Therap. Med.
– volume: 13
  start-page: 132
  year: 2015
  ident: bb0650
  article-title: miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1 (DNMT1) expression
  publication-title: J. Transl. Med.
– year: 2019
  ident: bb0410
  article-title: MiR-34c Downregulation Leads to SOX4 Overexpression and Cisplatin Resistance in Nasopharyngeal Carcinoma
– volume: 33
  start-page: 942
  year: 2015
  end-page: 950
  ident: bb0530
  article-title: miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist
  publication-title: Oncol. Rep.
– volume: 10
  start-page: 2717
  year: 2017
  end-page: 2726
  ident: bb0645
  article-title: Long noncoding RNA HOTAIR promotes cisplatin resistance in gastric cancer through promoting WIF-1 promoter methylation
  publication-title: Int. J. Clin. Exp. Med.
– volume: 118
  start-page: 233
  year: 2018
  end-page: 241
  ident: bb0505
  article-title: Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway
  publication-title: Neurochem. Int.
– volume: 124
  start-page: 109740
  year: 2020
  ident: bb0565
  article-title: Long noncoding RNA LINC00461 mediates cisplatin resistance of rectal cancer via miR-593-5p/CCND1 axis
  publication-title: Biomed. Pharmacother.
– volume: 111817
  year: 2020
  ident: bb0880
  article-title: A novel miR-200c/c-myc negative regulatory feedback loop is essential to the EMT process, CSC biology and drug sensitivity in nasopharyngeal cancer
  publication-title: Exp. Cell Res.
– volume: 39
  year: 2019
  ident: bb0515
  article-title: LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a/HMGA2 axis
  publication-title: Biosci. Rep.
– volume: 37
  start-page: 6837
  year: 2016
  end-page: 6845
  ident: bb1070
  article-title: miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis
  publication-title: Tumor Biol.
– volume: 101
  start-page: 536
  year: 2018
  end-page: 542
  ident: bb0160
  article-title: LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation
  publication-title: Biomed. Pharmacother.
– volume: 106
  start-page: 1357
  year: 2018
  end-page: 1363
  ident: bb9237
  article-title: MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R
  publication-title: BioMed. & Pharmacother.
– volume: 37
  start-page: 16345
  year: 2016
  end-page: 16355
  ident: bb0870
  article-title: LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes
  publication-title: Tumor Biol.
– volume: 8
  start-page: 1
  year: 2019
  end-page: 13
  ident: bb0385
  article-title: LncRNA HOXA-AS3 confers cisplatin resistance by interacting with HOXA3 in non-small-cell lung carcinoma cells
  publication-title: Oncogenesis.
– volume: 7
  start-page: 37524
  year: 2016
  ident: bb0915
  article-title: Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2
  publication-title: Oncotarget.
– start-page: 1
  year: 2020
  end-page: 14
  ident: bb0770
  article-title: The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells
  publication-title: RNA Biol.
– volume: 740
  start-page: 364
  year: 2014
  end-page: 378
  ident: bb0115
  article-title: Cisplatin in cancer therapy: molecular mechanisms of action
  publication-title: Eur. J. Pharmacol.
– volume: 108
  start-page: 23
  year: 2017
  end-page: 31
  ident: bb0635
  article-title: miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells
  publication-title: Cancer Sci.
– volume: 34
  start-page: 28
  year: 2015
  ident: bb1075
  article-title: MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7
  publication-title: J. Exp. Clin. Cancer Res.
– volume: 17
  start-page: 574
  year: 2010
  end-page: 583
  ident: bb0280
  article-title: Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator
  publication-title: Cancer Cell
– volume: 10
  start-page: 159
  year: 2020
  end-page: 170
  ident: bb2045
  article-title: Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics
  publication-title: Acta Pharma. Sin. B
– volume: 51
  start-page: 2160
  year: 2018
  end-page: 2171
  ident: bb0665
  article-title: miR-202 enhances the anti-tumor effect of cisplatin on non-small cell lung cancer by targeting the Ras/MAPK pathway
  publication-title: Cell. Physiol. Biochem.
– volume: 6
  start-page: 14885
  year: 2015
  ident: bb0145
  article-title: Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1–miR-593-5p–MFF axis
  publication-title: Oncotarget
– volume: 20
  start-page: 559
  year: 2016
  end-page: 567
  ident: bb0955
  article-title: miR-222 attenuates cisplatin-induced cell death by targeting the PPP 2R2A/Akt/mTOR Axis in bladder cancer cells
  publication-title: J. Cell. Mol. Med.
– volume: 35
  start-page: 2087
  year: 2016
  end-page: 2097
  ident: bb0540
  article-title: Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1
  publication-title: Oncogene.
– volume: 115
  start-page: 108869
  year: 2019
  ident: bb0785
  article-title: Downregulation of long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression
  publication-title: Biomed. Pharmacother.
– volume: 112
  start-page: 108633
  year: 2019
  ident: bb1050
  article-title: Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204
  publication-title: Biomed. Pharmacother.
– volume: 12
  start-page: 856
  issue: 4
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0100
  article-title: CD44s induces miR-629-3p expression in association with cisplatin resistance in head and neck cancer cells
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12040856
– volume: 576
  start-page: 828
  issue: 2
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb1025
  article-title: MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin
  publication-title: Gene.
  doi: 10.1016/j.gene.2015.11.013
– volume: 22
  start-page: 5867
  issue: 18
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb9244
  article-title: MiR-100 up-regulation enhanced cell autophagy and apoptosis induced by cisplatin in osteosarcoma by targeting mTOR
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 22
  start-page: 1328
  issue: 8
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0225
  article-title: Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth
  publication-title: Cell Death Differ.
  doi: 10.1038/cdd.2014.221
– ident: 10.1016/j.yexmp.2021.104602_bb5000
– volume: 38
  start-page: 564
  issue: 4
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb9245
  article-title: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0459-x
– volume: 623
  start-page: 20
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0175
  article-title: Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin
  publication-title: Arch. Biochem. Biophys.
  doi: 10.1016/j.abb.2017.05.001
– volume: 33
  start-page: 981
  issue: 2
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0685
  article-title: miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2014.3657
– volume: 39
  issue: 6
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb2025
  article-title: Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells
  publication-title: Tumor Biol.
  doi: 10.1177/1010428317715155
– volume: 35
  start-page: 323
  issue: 3
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb1105
  article-title: miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin
  publication-title: Oncogene.
  doi: 10.1038/onc.2015.84
– volume: 37
  start-page: 2565
  issue: 2
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0580
  article-title: Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-015-4081-z
– volume: 36
  start-page: 53
  issue: 1
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb1035
  article-title: Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-017-0528-y
– volume: 21
  start-page: 2650
  issue: 11
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0945
  article-title: MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 5
  start-page: 100103
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0710
  article-title: MicroRNA-135a promotes proliferation, migration, invasion and induces chemoresistance of endometrial cancer cells
  publication-title: Eur. J. Obstetr. Gynecol. Reprod. Biol. X.
  doi: 10.1016/j.eurox.2019.100103
– volume: 12
  start-page: 2001
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0680
  article-title: LncRNA-ATB Promotes Cisplatin Resistance in Lung Adenocarcinoma Cells by Targeting the miR-200a/β-Catenin Pathway
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S240695
– volume: 10
  start-page: 5137
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0735
  article-title: LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S146423
– volume: 34
  start-page: 368
  issue: 1
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0925
  article-title: miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2015.3996
– volume: 9
  start-page: 402
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0520
  article-title: Overview of MicroRNA biogenesis, mechanisms of actions, and circulation
  publication-title: Front. Endocrinol. (Lausanne)
  doi: 10.3389/fendo.2018.00402
– volume: 469
  start-page: 266
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0585
  article-title: MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2019.10.044
– volume: 10
  issue: 2
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0325
  article-title: miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0117809
– volume: 105195
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0805
  article-title: PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma
  publication-title: Pharmacol. Res.
– volume: 108
  start-page: 23
  issue: 1
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0635
  article-title: miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells
  publication-title: Cancer Sci.
  doi: 10.1111/cas.13104
– volume: 62
  start-page: 432
  issue: 3
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0695
  article-title: Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells
  publication-title: Neoplasma.
  doi: 10.4149/neo_2015_051
– volume: 22
  start-page: 1249
  issue: 5
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0465
  article-title: Down-regulation of miR-377 contributes to cisplatin resistance by targeting XIAP in osteosarcoma
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 9
  start-page: 7501
  issue: 7
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0700
  article-title: MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.23483
– volume: 22
  start-page: 4879
  issue: 15
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0035
  article-title: LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 54
  start-page: 239
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb9252
  article-title: LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA-30b/autophagy-related gene 5 axis in gastric cancer
  publication-title: Int. J. Oncol.
– volume: 17
  start-page: 92
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb9255
  article-title: lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143/FOSL2-signaling pathway in ovarian cancer
  publication-title: Mol. Ther. Nucleic Acids
  doi: 10.1016/j.omtn.2019.05.007
– volume: 9
  start-page: 1354
  issue: 7
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0285
  article-title: Emerging roles of lncRNA in cancer and therapeutic opportunities
  publication-title: Am. J. Cancer Res.
– year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb9254
  article-title: PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2
  publication-title: J. Cell. Biochem.
– volume: 9
  start-page: 24457
  issue: 36
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0625
  article-title: Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.25326
– volume: 13
  start-page: 2887
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0890
  article-title: miR-34c targets MET to improve the anti-tumor effect of cisplatin on Ovarian Cancer
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S239425
– volume: 109
  start-page: 902
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0615
  article-title: MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.10.080
– volume: 7
  start-page: 1
  issue: 1
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0150
  article-title: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway
  publication-title: Sci. Rep.
– volume: 22
  start-page: 3506
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0155
  article-title: Long non-coding RNA (LncRNA) urothelial carcinoma associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b
  publication-title: Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.
– volume: 382
  start-page: 137
  issue: 2
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0765
  article-title: Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2016.08.024
– volume: 19
  start-page: 250
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb1040
  article-title: miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-019-0943-6
– volume: 51
  start-page: 456
  issue: 9
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0045
  article-title: MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition
  publication-title: BMB Rep.
  doi: 10.5483/BMBRep.2018.51.9.104
– volume: 12
  start-page: 6105
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0190
  article-title: lncRNA FOXD2-AS1 confers cisplatin resistance of non-small-cell lung cancer via regulation of miR185-5p–SIX1 axis
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S197454
– volume: 12
  start-page: 7551
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0950
  article-title: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S212649
– volume: 39
  start-page: 1631
  issue: 4
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0435
  article-title: miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway
  publication-title: Oncol. Rep.
– volume: 118
  start-page: 233
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0505
  article-title: Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway
  publication-title: Neurochem. Int.
  doi: 10.1016/j.neuint.2018.03.011
– volume: 8
  start-page: 61
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0845
  article-title: TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2
  publication-title: Cell Biosci.
  doi: 10.1186/s13578-018-0260-0
– volume: 16
  start-page: 257
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb9247
  article-title: lncRNA TUG1 promotes cisplatin resistance by regulating CCND2 via epigenetically silencing miR-194-5p in bladder cancer
  publication-title: Mol. Ther. Nucleic Acids
  doi: 10.1016/j.omtn.2019.02.017
– volume: 18
  start-page: 404
  issue: 1
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb2040
  article-title: MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells
  publication-title: BMC cancer
  doi: 10.1186/s12885-018-4233-9
– volume: 49
  start-page: 808
  issue: 9
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0460
  article-title: Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma
  publication-title: Acta Biochim. Biophys. Sin.
  doi: 10.1093/abbs/gmx078
– volume: 482
  start-page: 22
  issue: 1
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0630
  article-title: miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2016.11.037
– volume: 106
  start-page: 1357
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb9237
  article-title: MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R
  publication-title: BioMed. & Pharmacother.
  doi: 10.1016/j.biopha.2018.07.059
– volume: 40
  issue: 3
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0800
  article-title: miR-492 promotes chemoresistance to CDDP and metastasis by targeting inhibiting DNMT3B and induces stemness in gastric cancer
  publication-title: Biosci. Rep.
  doi: 10.1042/BSR20194342
– volume: 21
  start-page: 135
  issue: 1
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0350
  article-title: miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal
  publication-title: Cancer Biom.
  doi: 10.3233/CBM-170452
– volume: 11
  start-page: 91
  issue: 1
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0050
  article-title: MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1
  publication-title: Bioengineered.
  doi: 10.1080/21655979.2019.1710925
– volume: 16
  start-page: 2946
  issue: 3
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb9259
  article-title: Long non-coding RNA MEG3 contributes to cisplatin-induced apoptosis via inhibition of autophagy in human glioma cells
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2017.6897
– volume: 7
  start-page: 24510
  issue: 17
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0570
  article-title: miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8229
– year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0410
– volume: 14
  start-page: 7986
  issue: 6
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb1055
  article-title: Knockdown of long non-coding RNA HOTAIR sensitizes hepatocellular carcinoma cell to cisplatin by suppressing the STAT3/ABCB1 signaling pathway
  publication-title: Oncol. Lett.
– volume: 37
  start-page: 2720
  issue: 5
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0750
  article-title: miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2017.5532
– volume: 23
  start-page: 7256
  issue: 17
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0085
  article-title: Long non-coding RNA ROR regulated ABCB1 to induce cisplatin resistance in osteosarcoma by sponging miR-153-3p
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 234
  start-page: 22581
  issue: 12
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0205
  article-title: The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.28823
– volume: 16
  start-page: 30
  issue: 1
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0355
  article-title: MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-016-0305-6
– volume: 16
  start-page: 2100
  issue: 21
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0655
  article-title: LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis
  publication-title: Cell Cycle
  doi: 10.1080/15384101.2017.1361071
– volume: 9
  start-page: 1
  issue: 5
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0760
  article-title: miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-018-0390-7
– volume: 17
  start-page: 1453
  issue: 2
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0440
  article-title: miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases
  publication-title: Oncol. Lett.
– volume: 8
  start-page: 97476
  issue: 57
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb9251
  article-title: Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.22138
– volume: 66
  start-page: 369
  issue: 3
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0885
  article-title: MiR-29a-mediated CD133 expression contributes to cisplatin resistance in CD133+ glioblastoma stem cells
  publication-title: J. Mol. Neurosci.
  doi: 10.1007/s12031-018-1177-0
– volume: 101
  start-page: 536
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0160
  article-title: LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.02.130
– volume: 20
  start-page: 3540
  issue: 14
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0315
  article-title: MiR-1208 Increases the Sensitivity to Cisplatin by Targeting TBCK in Renal Cancer Cells
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms20143540
– volume: 8
  start-page: 3314
  issue: 11
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0450
  article-title: Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patients
  publication-title: J. Thorac. Disease.
  doi: 10.21037/jtd.2016.11.75
– volume: 51
  start-page: 129
  issue: 1
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0295
  article-title: Recovery of miR-139-5p in ovarian cancer reverses cisplatin resistance by targeting C-Jun
  publication-title: Cell. Physiol. Biochem.
  doi: 10.1159/000495169
– volume: 572
  start-page: 116
  issue: 1
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0525
  article-title: Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1
  publication-title: Gene.
  doi: 10.1016/j.gene.2015.07.002
– volume: 200
  start-page: 45
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0610
  article-title: Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells
  publication-title: Clin. Exp. Immunol.
  doi: 10.1111/cei.13406
– year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0825
– volume: 6
  start-page: 26457
  issue: 28
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0860
  article-title: MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.4762
– volume: 18
  start-page: 974
  issue: 12
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0250
  article-title: LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4
  publication-title: Cancer Biol. Ther.
  doi: 10.1080/15384047.2017.1385679
– volume: 19
  start-page: 193
  issue: 2
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb9234
  article-title: miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway
  publication-title: Cell Cycle
  doi: 10.1080/15384101.2019.1704537
– volume: 10
  start-page: 159
  issue: 1
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb2045
  article-title: Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics
  publication-title: Acta Pharma. Sin. B
  doi: 10.1016/j.apsb.2019.11.001
– volume: 19
  start-page: 630
  issue: 1
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0940
  article-title: MicroRNA-138 inhibits tumor growth and enhances chemosensitivity in human cervical cancer by targeting H2AX
  publication-title: Exp. Therap. Med.
– volume: 15
  issue: 6
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb9243
  article-title: MiR-125b functions as a tumor suppressor and enhances chemosensitivity to cisplatin in osteosarcoma
  publication-title: Technol. Cancer Res. Treat.
  doi: 10.1177/1533034615618849
– volume: 8
  start-page: 39154
  issue: 24
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb1095
  article-title: IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.16610
– volume: 8
  start-page: 39154
  issue: 24
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb1100
  article-title: IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.16610
– volume: 37
  start-page: 1261
  issue: 1
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0130
  article-title: miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-015-3921-1
– volume: 12
  start-page: 4530
  issue: 3
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0815
  article-title: Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2015.3897
– volume: 9
  start-page: 2105
  issue: 2
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0995
  article-title: The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.23249
– volume: 29
  start-page: 1438
  issue: 12
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0095
  article-title: HOXD-AS1 exerts oncogenic functions and promotes chemoresistance in cisplatin-resistant cervical cancer cells
  publication-title: Hum. Gene Ther.
  doi: 10.1089/hum.2017.256
– volume: 235
  start-page: 5059
  issue: 6
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0005
  article-title: Critical roles of long noncoding RNAs in breast cancer
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.29442
– volume: 10
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0970
  article-title: A novel long non-coding RNA, MSTRG. 51053.2 regulates cisplatin resistance by sponging the miR-432-5p in non-small cell lung cancer cells
  publication-title: Front. Oncol.
– volume: 11
  issue: 3
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb1110
  article-title: MiR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0150026
– volume: 41
  start-page: 2050
  issue: 4
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0375
  article-title: miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells
  publication-title: Int. J. Mol. Med.
– volume: 14
  start-page: 745
  issue: 4
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0425
  article-title: miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2
  publication-title: Arch. Med. Sci.
– volume: 38
  issue: 4
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0300
  article-title: STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance
  publication-title: Biosci. Rep.
  doi: 10.1042/BSR20180547
– volume: 8
  start-page: 20565
  issue: 11
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0405
  article-title: Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways
  publication-title: Int. J. Clin. Exp. Med.
– volume: 37
  start-page: 16345
  issue: 12
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0870
  article-title: LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-016-5448-5
– volume: 37
  start-page: 6837
  issue: 5
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb1070
  article-title: miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-015-4500-1
– volume: 35
  start-page: 204
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0215
  article-title: The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells
  publication-title: EBioMedicine.
  doi: 10.1016/j.ebiom.2018.08.001
– volume: 10
  issue: 6
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0345
  article-title: MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells
  publication-title: PLoS One
– volume: 37
  start-page: 4509
  issue: 4
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0910
  article-title: Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-015-4267-4
– volume: 115
  start-page: 108869
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0785
  article-title: Downregulation of long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2019.108869
– volume: 21
  start-page: 2626
  issue: 11
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0500
  article-title: Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53-p66shc pathway
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 51
  start-page: 2160
  issue: 5
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0665
  article-title: miR-202 enhances the anti-tumor effect of cisplatin on non-small cell lung cancer by targeting the Ras/MAPK pathway
  publication-title: Cell. Physiol. Biochem.
  doi: 10.1159/000495835
– volume: 215
  start-page: 931
  issue: 5
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb8259
  article-title: Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro
  publication-title: Pathology-Research and Practice
  doi: 10.1016/j.prp.2019.01.042
– volume: 86
  start-page: 450
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0485
  article-title: MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2016.11.139
– volume: 80
  start-page: 973
  issue: 5
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0965
  article-title: miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/s00280-017-3435-1
– volume: 112
  start-page: 108633
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb1050
  article-title: Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2019.108633
– volume: 16
  start-page: 827
  issue: 5
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0025
  article-title: Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.32460
– volume: 20
  start-page: 559
  issue: 3
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0955
  article-title: miR-222 attenuates cisplatin-induced cell death by targeting the PPP 2R2A/Akt/mTOR Axis in bladder cancer cells
  publication-title: J. Cell. Mol. Med.
  doi: 10.1111/jcmm.12760
– volume: 12
  start-page: 9513
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0725
  article-title: miR-152-3p sensitizes glioblastoma cells towards cisplatin via regulation of SOS1
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S210732
– volume: 36
  start-page: 275
  issue: 2
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb2005
  article-title: miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin
  publication-title: Oncogene
  doi: 10.1038/onc.2016.201
– volume: 41
  start-page: 973
  issue: 3
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0220
  article-title: A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells
  publication-title: Cell. Physiol. Biochem.
  doi: 10.1159/000460618
– volume: 13
  start-page: 109
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0895
  article-title: miR-1269b drives cisplatin resistance of human non-small cell lung cancer via modulating the PTEN/PI3K/AKT signaling pathway
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S225010
– volume: 7
  start-page: 53254
  issue: 33
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb1015
  article-title: MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.10736
– volume: 13
  start-page: 99
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0795
  article-title: NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis
  publication-title: J. Cell Commun. Signal.
  doi: 10.1007/s12079-018-0479-x
– volume: 17
  start-page: 574
  issue: 6
  year: 2010
  ident: 10.1016/j.yexmp.2021.104602_bb0280
  article-title: Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2010.04.011
– volume: 14
  start-page: 1742
  issue: 2
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb1085
  article-title: miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2016.5413
– volume: 107
  start-page: 338
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0675
  article-title: Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.07.076
– volume: 8
  start-page: 1
  issue: 1
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0120
  article-title: MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway
  publication-title: Sci. Rep.
– volume: 7
  start-page: 37524
  issue: 25
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0915
  article-title: Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.6852
– volume: 16
  start-page: 1
  issue: 1
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb2035
  article-title: KLF4, a miR-32-5p targeted gene, promotes cisplatin-induced apoptosis by upregulating BIK expression in prostate cancer
  publication-title: Cell Comm. Signal.
  doi: 10.1186/s12964-018-0270-x
– volume: 23
  start-page: 4185
  issue: 10
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0340
  article-title: LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 15
  start-page: e0223035
  issue: 11
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0490
  article-title: LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1
  publication-title: PLoS One.
  doi: 10.1371/journal.pone.0223035
– volume: 12
  start-page: 233
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0930
  article-title: miR106a promotes the growth of transplanted breast cancer and decreases the sensitivity of transplanted tumors to Cisplatin
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S231375
– volume: 24
  start-page: 200
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0550
  article-title: LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 121
  start-page: 1675
  issue: 2
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0135
  article-title: MiR-1827 functions as a tumor suppressor in lung adenocarcinoma by targeting MYC and FAM83F
  publication-title: J. Cell. Biochem.
  doi: 10.1002/jcb.29402
– volume: 2019
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0755
  article-title: LncRNA HOXA11-AS promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by suppression of miR-214-3p expression
  publication-title: Biomed. Res. Int.
– volume: 15
  start-page: 731
  issue: 1
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb1020
  article-title: The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer
  publication-title: BMC Cancer
  doi: 10.1186/s12885-015-1713-z
– volume: 11
  start-page: 1157
  issue: 13
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0320
  article-title: Exosome mediated miR-155 delivery confers cisplatin chemoresistance in oral cancer cells via epithelial-mesenchymal transition
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.27531
– volume: 46
  start-page: 831
  issue: 5
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0495
  article-title: MicroRNA-31 weakens cisplatin resistance of medulloblastoma cells via NF-κB and PI3K/AKT pathways
  publication-title: BioFactors.
  doi: 10.1002/biof.1616
– volume: 20
  start-page: 1
  issue: 1
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb9257
  article-title: Inhibition of ZEB1–AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-020-1164-8
– volume: 93
  start-page: 570
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0040
  article-title: GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2017.06.089
– volume: 62
  start-page: 1154
  issue: 5
  year: 2002
  ident: 10.1016/j.yexmp.2021.104602_bb0395
  article-title: The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.62.5.1154
– volume: 31
  start-page: 473
  issue: 5
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0330
  article-title: Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axis
  publication-title: Anti-Cancer Drugs
  doi: 10.1097/CAD.0000000000000888
– volume: 35
  start-page: 2087
  issue: 16
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0540
  article-title: Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1
  publication-title: Oncogene.
  doi: 10.1038/onc.2015.271
– volume: 114
  start-page: 108662
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0575
  article-title: MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2019.108662
– volume: 51
  start-page: 1148
  issue: 11
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0455
  article-title: LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer
  publication-title: Acta Biochim. Biophys. Sin.
  doi: 10.1093/abbs/gmz112
– volume: 120
  start-page: 9656
  issue: 6
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0640
  article-title: Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p
  publication-title: J. Cell. Biochem.
  doi: 10.1002/jcb.28244
– volume: 12
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0125
  article-title: EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S214104
– volume: 1
  start-page: 1
  issue: 1
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0535
  article-title: The role of MicroRNAs in human cancer
  publication-title: Signal Transd. Target. Ther.
– volume: 7
  start-page: 43109
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb5500
  article-title: miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer
  publication-title: Scientific reports
  doi: 10.1038/srep43109
– volume: 10
  issue: 3
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0900
  article-title: Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small cell lung cancer to cisplatin
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0121547
– volume: 19
  start-page: 1
  issue: 1
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0960
  article-title: CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-020-01168-8
– volume: 43
  start-page: 1169
  issue: 4
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0510
  article-title: MicroRNA-22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway
  publication-title: Oncol. Rep.
– volume: 71
  start-page: 598
  issue: 10
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0705
  article-title: Knockdown of long noncoding RNA urothelial cancer-associated 1 enhances cisplatin chemosensitivity in tongue squamous cell carcinoma cells
  publication-title: Die Pharm. Int. J. Pharm. Sci.
– volume: 24
  start-page: 1688
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0935
  article-title: MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 83
  start-page: 921
  issue: 5
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb9249
  article-title: The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/s00280-019-03808-3
– year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb9248
  article-title: LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling
  publication-title: J. Biochem. Mol. Toxicol.
  doi: 10.1002/jbt.22452
– volume: 11
  start-page: 12328
  issue: 24
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0480
  article-title: Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis
  publication-title: Aging (Albany NY)
  doi: 10.18632/aging.102575
– volume: 14
  start-page: 8121
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb2015
  article-title: Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S221383
– volume: 28
  start-page: 204
  issue: 2
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb1065
  article-title: Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling
  publication-title: J. Drug Target.
  doi: 10.1080/1061186X.2019.1644651
– volume: 36
  start-page: 2065
  issue: 3
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0230
  article-title: MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-014-2814-z
– volume: 12
  start-page: 1437
  issue: 12
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb1005
  article-title: MiR-99a and MiR-491 regulate cisplatin resistance in human gastric cancer cells by targeting CAPNS1
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.16529
– volume: 6
  start-page: 2897
  issue: 12
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0170
  article-title: LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression
  publication-title: Cancer Med.
  doi: 10.1002/cam4.1253
– volume: 20
  start-page: 2271
  issue: 11
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0985
  article-title: GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 18
  start-page: 25
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb1120
  article-title: MiR-126 enhances cisplatin chemosensitivity in hepatocellular carcinoma cells by targeting IRS1
  publication-title: Trop. J. Pharm. Res.
  doi: 10.4314/tjpr.v18i1.4
– volume: 16
  start-page: 4107
  issue: 4
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0400
  article-title: Long non-coding RNA AK001796 contributes to cisplatin resistance of non-small cell lung cancer
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2017.7081
– volume: 521
  start-page: 271
  issue: 2
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0370
  article-title: Up-regulated lnc-lung cancer associated transcript 1 enhances cell migration and invasion in breast cancer progression
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2019.08.040
– volume: 56
  start-page: 2022
  issue: 9
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0975
  article-title: Upregulated miR-132 in Lgr5+ gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway
  publication-title: Mol. Carcinog.
  doi: 10.1002/mc.22656
– volume: 111817
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0880
  article-title: A novel miR-200c/c-myc negative regulatory feedback loop is essential to the EMT process, CSC biology and drug sensitivity in nasopharyngeal cancer
  publication-title: Exp. Cell Res.
– volume: 70
  start-page: 203
  issue: 1
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0015
  article-title: MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway
  publication-title: Cytotechnology
  doi: 10.1007/s10616-017-0134-z
– volume: 10
  start-page: 1039
  issue: 4
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0840
  article-title: MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells
  publication-title: J. Cancer
  doi: 10.7150/jca.25814
– volume: 8
  start-page: 1
  issue: 1
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0850
  article-title: TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2
  publication-title: Cell Biosci.
  doi: 10.1186/s13578-018-0260-0
– volume: 22
  start-page: 299
  issue: 2
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb9240
  article-title: MiR-205 enhances cisplatin sensitivity of glioma cells by targeting E2F1
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 10
  start-page: 280
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0365
  article-title: Long non-coding RNA DLEU1 promotes cell proliferation, invasion and confers cisplatin resistance in bladder cancer by regulating the miR-99b/HS3ST3B1 axis
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2019.00280
– volume: 28
  start-page: 65
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0420
  article-title: Overexpression of the long non-coding RNA FOXD2-AS1 promotes cisplatin resistance in esophageal squamous cell carcinoma through the miR-195-Akt-mTOR axis
  publication-title: Oncol. Res. Featur. Preclin. Clin. Cancer Therap.
  doi: 10.1007/s00432-018-2761-y
– volume: 34
  start-page: 28
  issue: 1
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb1075
  article-title: MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-015-0145-6
– year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0445
  article-title: miR-451 selectively increases sensitivity to cisplatin in ERCC1-high non-small cell lung cancer cells
  publication-title: J. Cell. Biochem.
– volume: 5
  start-page: 17618
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0745
  article-title: MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC
  publication-title: Sci. Rep.
  doi: 10.1038/srep17618
– volume: 11
  start-page: 2551
  issue: 9
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0865
  article-title: MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway
  publication-title: Aging (Albany NY)
  doi: 10.18632/aging.101876
– volume: 47
  start-page: 1432
  issue: 4
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb2020
  article-title: Knockdown of MiR-20a enhances sensitivity of colorectal Cancer cells to cisplatin by increasing ASK1 expression
  publication-title: Cell. Physiol. Biochem.
  doi: 10.1159/000490834
– volume: 26
  start-page: 632
  issue: 6
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb9253
  article-title: Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression
  publication-title: Anti-Cancer Drugs
  doi: 10.1097/CAD.0000000000000227
– volume: 13
  start-page: 2783
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0905
  article-title: Long Non-Coding RNA SPRY4-IT1 Reverses Cisplatin Resistance by Downregulating MPZL-1 via Suppressing EMT in NSCLC
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S232769
– volume: 22
  start-page: 5490
  issue: 17
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb2030
  article-title: The increase of miR-27a affects the role of cisplatin on proliferation and migration capacities of liver cancer cells
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 9
  start-page: 1
  issue: 7
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0990
  article-title: LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-018-0793-5
– volume: 43
  start-page: 12
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0920
  article-title: miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1
  publication-title: Cell Biol. Int.
  doi: 10.1002/cbin.11071
– volume: 6
  start-page: 14885
  issue: 17
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0145
  article-title: Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1–miR-593-5p–MFF axis
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3659
– volume: 19
  start-page: 534
  issue: 6
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0415
  article-title: LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway
  publication-title: Cancer Biol. Ther.
  doi: 10.1080/15384047.2018.1450119
– volume: 121
  start-page: 1353
  issue: 2
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0335
  article-title: PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2
  publication-title: J. Cell. Biochem.
  doi: 10.1002/jcb.29370
– volume: 74
  start-page: 2613
  issue: 14
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb1000
  article-title: Emerging role of MicroRNAs in mTOR signaling
  publication-title: Cell. Mol. Life Sci.
  doi: 10.1007/s00018-017-2485-1
– volume: 7
  start-page: 86446
  issue: 52
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb9241
  article-title: Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13424
– volume: 8
  start-page: 2558
  issue: 2
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb9258
  article-title: Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13708
– volume: 20
  start-page: 3355
  issue: 4
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0830
  article-title: Cisplatin decreases cyclin D2 expression via upregulating miR-93 to inhibit lung adenocarcinoma cell growth
  publication-title: Mol. Med. Rep.
– volume: 12
  start-page: 1929
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0110
  article-title: LncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K/AKT pathway
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S243796
– volume: 9
  start-page: 1127
  issue: 3
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0690
  article-title: MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2
  publication-title: Am. J. Transl. Res.
– volume: 11
  start-page: 2138
  issue: 7
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0260
  article-title: MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway
  publication-title: Aging (Albany NY)
  doi: 10.18632/aging.101907
– volume: 124
  start-page: 109740
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0565
  article-title: Long noncoding RNA LINC00461 mediates cisplatin resistance of rectal cancer via miR-593-5p/CCND1 axis
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2019.109740
– volume: 33
  start-page: 382
  issue: 6
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb1090
  article-title: miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5
  publication-title: J. Biomed. Res.
  doi: 10.7555/JBR.33.20180078
– volume: 33
  start-page: 942
  issue: 2
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0530
  article-title: miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2014.3664
– start-page: 1
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0770
  article-title: The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells
  publication-title: RNA Biol.
– volume: 64
  start-page: 706
  issue: 3
  year: 2012
  ident: 10.1016/j.yexmp.2021.104602_bb0600
  article-title: Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes
  publication-title: Pharmacol. Rev.
  doi: 10.1124/pr.111.005637
– volume: 17
  start-page: 1664
  issue: 2
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0070
  article-title: MicroRNA-504 modulates osteosarcoma cell chemoresistance to cisplatin by targeting p53
  publication-title: Oncol. Lett.
– volume: 19
  start-page: 533
  issue: 1
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0270
  article-title: Knockdown of lncRNA MIAT inhibits proliferation and cisplatin resistance in non-small cell lung cancer cells by increasing miR-184 expression
  publication-title: Oncol Lett.
– volume: 24
  start-page: 208
  issue: 5
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0475
  article-title: MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1
  publication-title: Cancer Gene Ther.
  doi: 10.1038/cgt.2017.6
– volume: 740
  start-page: 364
  year: 2014
  ident: 10.1016/j.yexmp.2021.104602_bb0115
  article-title: Cisplatin in cancer therapy: molecular mechanisms of action
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2014.07.025
– volume: 36
  start-page: 2737
  issue: 4
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb1115
  article-title: Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-014-2898-5
– volume: 39
  issue: 11
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0310
  article-title: Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α
  publication-title: Biosci. Rep.
  doi: 10.1042/BSR20170080
– volume: 39
  issue: 7
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0515
  article-title: LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a/HMGA2 axis
  publication-title: Biosci. Rep.
  doi: 10.1042/BSR20182101
– volume: 55
  start-page: 988
  issue: 5
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb9256
  article-title: LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR-9-5p and regulating SPAG9 expression
  publication-title: Int. J. Oncol.
– volume: 235
  start-page: 1247
  issue: 2
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb2010
  article-title: microRNA‐10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.29040
– volume: 22
  start-page: 4440
  issue: 14
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0855
  article-title: LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 7
  start-page: 4598
  issue: 9
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb9236
  article-title: MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
  publication-title: Cancer Med.
  doi: 10.1002/cam4.1682
– volume: 7
  start-page: 43337
  issue: 28
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0290
  article-title: NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.9712
– volume: 38
  issue: 4
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0305
  article-title: STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance
  publication-title: Biosci. Rep.
  doi: 10.1042/BSR20180547
– volume: 88
  start-page: 507
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb9239
  article-title: MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM)
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2017.01.058
– volume: 107
  start-page: 2620
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0080
  article-title: Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a
  publication-title: Int. J. Biol. Macromol.
  doi: 10.1016/j.ijbiomac.2017.10.154
– volume: 8
  start-page: 1
  issue: 11
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0385
  article-title: LncRNA HOXA-AS3 confers cisplatin resistance by interacting with HOXA3 in non-small-cell lung carcinoma cells
  publication-title: Oncogenesis.
  doi: 10.1038/s41389-019-0170-y
– volume: 47
  start-page: 2077
  issue: 5
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0780
  article-title: miR-100 reverses cisplatin resistance in breast Cancer by suppressing HAX-1
  publication-title: Cell. Physiol. Biochem.
  doi: 10.1159/000491476
– volume: 497
  start-page: 827
  issue: 3
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0670
  article-title: miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2018.02.091
– volume: 6
  start-page: 26093
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb1045
  article-title: The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in high-grade serous ovarian cancer
  publication-title: Sci. Rep.
  doi: 10.1038/srep26093
– volume: 19
  start-page: 1797
  issue: 3
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb1080
  article-title: MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1
  publication-title: Exp. Therap. Med.
– volume: 7
  start-page: 1
  issue: 5
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0030
  article-title: Dysregulation of the MiR-449b target TGFBI alters the TGFβ pathway to induce cisplatin resistance in nasopharyngeal carcinoma
  publication-title: Oncogenesis.
  doi: 10.1038/s41389-018-0050-x
– volume: 23
  start-page: 5229
  issue: 12
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0740
  article-title: Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 13
  start-page: 132
  issue: 1
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0650
  article-title: miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1 (DNMT1) expression
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-015-0488-y
– volume: 12
  start-page: 11057
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0090
  article-title: Knockdown Of lncRNA NCK-AS1 Regulates Cisplatin Resistance Through Modulating miR-137 In Osteosarcoma Cells
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S228199
– volume: 242
  start-page: 117162
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0020
  article-title: MiR-21 modulates the polarization of macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2019.117162
– volume: 120
  start-page: 243
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0065
  article-title: The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer
  publication-title: J. Cell. Biochem.
  doi: 10.1002/jcb.27327
– volume: 40
  start-page: 883
  issue: 7
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0390
  article-title: miR-338-5p inhibits cell proliferation, colony formation, migration and cisplatin resistance in esophageal squamous cancer cells by targeting FERMT2
  publication-title: Carcinogenesis.
  doi: 10.1093/carcin/bgy189
– volume: 12
  start-page: 3721
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0560
  article-title: Cisplatin-resistant lung cancer cell–derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100–5p-dependent manner
  publication-title: Int. J. Nanomedicine
  doi: 10.2147/IJN.S131516
– volume: 468
  start-page: 14
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0720
  article-title: SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2019.10.004
– volume: 70
  start-page: 1390
  issue: 4
  year: 2006
  ident: 10.1016/j.yexmp.2021.104602_bb0235
  article-title: Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.106.022624
– volume: 23
  start-page: 1093
  issue: 3
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0180
  article-title: LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 43
  start-page: 1906
  issue: 6
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0265
  article-title: miR-10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway
  publication-title: Oncol. Rep.
– volume: 10
  start-page: 1278
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb2000
  article-title: Targeted inhibition of miR-221/222 promoted cell sensitivity to cisplatin in triple negative breast cancer
  publication-title: Front. Genet.
– volume: 22
  start-page: 108
  issue: 3
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb1030
  article-title: miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells
  publication-title: Cancer Gene Ther.
  doi: 10.1038/cgt.2014.73
– volume: 591
  start-page: 636
  issue: 4
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0210
  article-title: Suppression of EIF 4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells
  publication-title: FEBS Lett.
  doi: 10.1002/1873-3468.12566
– volume: 22
  start-page: 7653
  issue: 22
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0730
  article-title: MALAT1 promotes cisplatin resistance in cervical cancer by activating the PI3K/AKT pathway
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 39
  start-page: 1649
  issue: 4
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0105
  article-title: miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8
  publication-title: Oncol. Rep.
– volume: 11
  start-page: 945
  issue: 2
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb0790
  article-title: miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9
  publication-title: Oncol. Lett.
  doi: 10.3892/ol.2015.4000
– volume: 21
  start-page: 4064
  issue: 18
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0715
  article-title: BCAR4 increase cisplatin resistance and predicted poor survival in gastric cancer patients
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 9
  start-page: 555
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0620
  article-title: miR-205-5p mediated downregulation of PTEN contributes to cisplatin resistance in C13K human ovarian cancer cells
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2018.00555
– volume: 395
  start-page: 507
  issue: 10223
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0055
  article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30211-7
– volume: 8
  start-page: 22003
  issue: 13
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0835
  article-title: MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.15781
– volume: 33
  start-page: 591
  issue: 2
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb1010
  article-title: Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2014.3640
– volume: 10
  start-page: 2717
  issue: 2
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0645
  article-title: Long noncoding RNA HOTAIR promotes cisplatin resistance in gastric cancer through promoting WIF-1 promoter methylation
  publication-title: Int. J. Clin. Exp. Med.
– volume: 120
  start-page: 2940
  issue: 3
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0820
  article-title: MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy
  publication-title: J. Cell. Biochem.
  doi: 10.1002/jcb.26865
– volume: 33
  start-page: 264
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0595
  article-title: Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer
  publication-title: FASEB J.
  doi: 10.1096/fj.201701456RR
– volume: 39
  start-page: 1477
  issue: 10
  year: 2017
  ident: 10.1016/j.yexmp.2021.104602_bb0660
  article-title: Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells
  publication-title: Biotechnol. Lett.
  doi: 10.1007/s10529-017-2392-4
– volume: 362
  start-page: 183
  issue: 2
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0140
  article-title: miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2015.03.045
– volume: 23
  start-page: 4220
  issue: 10
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0590
  article-title: Long noncoding RNA OR3A4 promotes cisplatin resistance of non-small cell lung cancer by upregulating CDK1
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 20
  start-page: 12
  issue: 1
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0555
  article-title: Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5
  publication-title: Genome Biol.
  doi: 10.1186/s13059-018-1604-0
– volume: 48
  start-page: 1737
  issue: 4
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb1060
  article-title: miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2016.3392
– volume: 47
  start-page: 1603
  issue: 4
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0075
  article-title: miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2015.3143
– volume: 19
  start-page: 375
  issue: 1
  year: 2020
  ident: 10.1016/j.yexmp.2021.104602_bb0605
  article-title: miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC
  publication-title: Exp. Therap. Med.
– volume: 20
  start-page: 1733
  issue: 9
  year: 2016
  ident: 10.1016/j.yexmp.2021.104602_bb9242
  article-title: MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT)
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 38
  issue: 3
  year: 2018
  ident: 10.1016/j.yexmp.2021.104602_bb0255
  article-title: Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma
  publication-title: Biosci. Rep.
  doi: 10.1042/BSR20180375
– volume: 161
  start-page: 98
  year: 2019
  ident: 10.1016/j.yexmp.2021.104602_bb0360
  article-title: miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2019.01.009
– volume: 99
  start-page: 14298
  issue: 22
  year: 2002
  ident: 10.1016/j.yexmp.2021.104602_bb0275
  article-title: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.162491399
– volume: 10
  issue: 5
  year: 2015
  ident: 10.1016/j.yexmp.2021.104602_bb0430
  article-title: The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0114586
SSID ssj0009012
Score 2.4741745
SecondaryResourceType review_article
Snippet Cisplatin is an extensively used chemotherapeutic substance for various types of human malignancies including sarcomas, carcinomas and lymphomas. Yet, the vast...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 104602
SubjectTerms Apoptosis - drug effects
Cell Proliferation - drug effects
chemoresistance
Cisplatin
Cisplatin - adverse effects
Cisplatin - therapeutic use
Drug Resistance, Neoplasm - genetics
Gene Expression Regulation, Neoplastic - drug effects
Humans
lncRNA
MicroRNAs - genetics
miRNA
Neoplasms - drug therapy
Neoplasms - genetics
Progression-Free Survival
RNA, Long Noncoding - genetics
Title LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin
URI https://dx.doi.org/10.1016/j.yexmp.2021.104602
https://www.ncbi.nlm.nih.gov/pubmed/33422487
https://www.proquest.com/docview/2476844596
Volume 123
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hKlEuVaGULi3ISD2SksROHB9Xq6KFhT2gIpB6sBw_pCA2uyKLBBd-ez1JTIUEHDjlIVuxZiaeb-zPMwA_TclFYbiL8iwVEdOGR0rkLlJpqgXTyocUuDRwNs3HF-zkKrtagVE4C4O0yn7u7-b0drbu3xz20jxcVBWe8fXBQNEGLYhUMG5njKOV_3r8T_Pw_q7LGJ6wCFuHzEMtx-vB3s8waWWatHud_drKC97pNfTZeqGjz_Cph49k2I1wA1ZsvQkfR6Fq2yasnfWb5V_g72mtz6fDhqjakFnV3i5UoFFbUtXEBDIMqofMHWmQz94VlMBHjTZxS3B1vyHLOdFVs0DyXL0FF0e__4zGUV9LIdI0E8uI2RixkWZKMap9kOUS54yyNklja52j3FGRFz58KFmiYk2Z4LoseazLWNsso19htZ7X9huQkpauMMwDl0IzE4vCK8D539zkOsu5cQNIgwyl7hONY72LGxkYZdeyFbxEwctO8AM4eOq06PJsvN08D8qRz8xFek_wdsf9oErpNYPyU7Wd3zUyZbgnyTKRD2C70_HTSChlHuoUfOe9n_0O6_jU8WB-wOry9s7uejSzLPdac92DD8PjyXiK18n55eQfXi70vw
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB2hRSq9VIVCu1CKkTg2IomdDx9XK9ACu3uoQELqwXL8IQV1syuySOXf40lsUCXg0FsSx4o149hv7Oc3ACe6KnipCxvlWcojpnQRSZ7bSKap4kxJF1Lg0sBsnk9u2OVtdrsB43AWBmmVfuzvx_RutPZPTr01T1d1jWd8XTBQdkELIhUXt2-iOlU2gM3RxdVk_qK9Gye9aHjCIqwQxIc6mtej-btA3co06bY7_fLKKxPUWwC0m4jOP8MnjyDJqG_kNmyYZge2xiFx2w58mPn98i_we9qoX_NRS2SjyaLuLlcyMKkNqRuiAx8GPUSWlrRIae9zSuCtwm5xT3CBvyXrJVF1u0L-XLMLN-dn1-NJ5NMpRIpmfB0xEyM8UkxKRpWLs2xirZbGJGlsjLW0sJTnpYsgKpbIWFHGC1VVRayqWJkso3swaJaN-QakopUtNXPYpVRMx7x0PrDuT9e5yvJC2yGkwYZCea1xTHnxRwRS2Z3oDC_Q8KI3_BB-Plda9VIb77-eB-eIf3qMcJPB-xWPgyuF8wzaTzZm-dCKlOG2JMt4PoSvvY-fW0Ipc2inLPb_97NHsDW5nk3F9GJ-dQAfsaSnxXyHwfr-wRw6cLOufvjO-wQXavXN
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LncRNAs+and+miRNAs+participate+in+determination+of+sensitivity+of+cancer+cells+to+cisplatin&rft.jtitle=Experimental+and+molecular+pathology&rft.au=Taheri%2C+Mohammad&rft.au=Shoorei%2C+Hamed&rft.au=Tondro+Anamag%2C+Farhad&rft.au=Ghafouri-Fard%2C+Soudeh&rft.date=2021-12-01&rft.eissn=1096-0945&rft.volume=123&rft.spage=104602&rft_id=info:doi/10.1016%2Fj.yexmp.2021.104602&rft_id=info%3Apmid%2F33422487&rft.externalDocID=33422487
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-4800&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-4800&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-4800&client=summon